Studies on subcellular localization of a moonlighting protein, enolase, and its foci formation

Natsuko MIURA

2013
CONTENTS

GENERAL INTRODUCTION 1

CHAPTER I  Searching for secretory pathway of enolase and discovery of enolase foci-forming region 26

CHAPTER II  Foci-formation of enolase under hypoxia 58
  Section 1  Determination of foci-forming region of enolase 67
  Section 2  Discovery of foci-formation of full-length enolase under hypoxia 73
  Section 3  Regulatory mechanisms of foci-formation of enolase 80
  Section 4  Biological roles of the enolase foci 85

CHAPTER III  Development of a novel method and an instrument to validate intracellular roles of extracellular moonlighting proteins 94

GENERAL CONCLUSION 108

ACKNOWLEDGEMENTS 109

PUBLICATIONS 110
GENERAL INTRODUCTION

In the post-genomic era, it is becoming increasingly important to analyze how molecules in a single cell play individual roles on each specific occasion. Proteins, one of the cellular components, were previously believed to have only a single function. Therefore, other molecules, such as RNAs or peptides, were believed to have multiple functions and to compensate for the small numbers of protein-coding genes in a cell. However, it is now clear that some proteins have more than one function. The discoveries in the 1980s that the lens protein crystallin is similar to glycolytic enzymes opened up the potentiality of proteins once again. The examples of multifunctional proteins, called “moonlighting proteins” by Jeffery in 1999, are increasing year by year. It is now reported that 10 of 10 glycolytic enzymes and 7 of 8 TCA cycle enzymes, as well as chaperones and histone proteins, are moonlighting proteins. Moonlighting proteins have different functions depending on their time or location of production. Therefore, analyzing changes in the localization of moonlighting proteins is highly important. Revealing how moonlighting proteins perform more than one function will disclose the hidden living machinery of the cell. Although some moonlighting proteins are reported to be functional outside the cell, their secretion machineries are not known in all organisms. Determining the translocation pathway of glycolytic enzymes will be a feasible approach to analyze the molecular basis of moonlighting. In addition, development of suitable cultivation methods for analyzing intercellular proteins is necessary for further research.

Moonlighting proteins—history, molecular mechanisms, and evolution

The word “moonlighting” had been used to mean “commit crimes at night” in 19th-century Ireland\(^1\)\(^2\), and now, this term is used as an informal intransitive verb to describe taking on a second job\(^2\)\. The compound term moonlighting proteins was first defined by Jeffery in 1999 (Jeffery 1999). According to Jeffery, moonlighting proteins are proteins with more than one function. These proteins are not cleaved or post-translationally modified, but they perform different functions in the same or in different locations (Jeffery 1999, Fig. 1).


The first examples of moonlighting proteins were lens crystallins, three of which were found to be identical to metabolic enzymes, namely lactate dehydrogenase, enolase, and aldolase (Wistow and Piatigorsky 1987, Piatigorsky and Wistow 1989, Piatigorsky 1998, Wistow et al. 1988). Surprisingly, these enzymes were purified from lens that retained enzymatic activity, suggesting that these proteins function as both structural proteins and metabolic enzymes (True and Carroll 2002, Graw 2009). A number of proteins have been subsequently found to have more than one function. A remarkable feature of moonlighting proteins is that, as a primary function, they often take part in central cellular processes such as transcription, translation, signaling, and metabolism (Fig. 2, Pancholi 2001). These proteins are also essential in the synthetic minimal genome created by Glass and colleagues (Glass et al. 2006).

Fig. 1 Moonlighting proteins

Fig. 2 Previously-known roles of moonlighting proteins (modified from Sriram et al. 2005)
Two important points arise when considering the importance of moonlighting proteins. First, because of the presence of moonlighting proteins, the living system can reduce the number of protein-coding genes. It is known that *Escherichia coli* has fewer number of protein-coding genes than the number of biological processes needed for survival (Thiele et al. 2009). With the help of moonlighting proteins, organisms can fill the gap and save energy to maintain a large number of gene sets. Second, these proteins possibly reflect the primitive form of proteins. The moonlighting abilities of proteins may have evolved over generations and diverged as homologs in the late stages of life (Piatigorsky et al. 2003). Indeed, most mammalian proteins have homologs that have different functions or localization sites in the cell. In some cases, the number of homologs is greater in “later” organisms, such as mammals, than in “earlier” organisms, such as prokaryotes (Jensen 1976, Parsot et al. 1987). Investigating how moonlighting proteins could have more than one function may reveal the features of polypeptides necessary to form organisms, to evolve, and to stand the test of immense amount of time.

The reason why moonlighting proteins can have more than one function or the molecular basis of moonlighting proteins is not completely understood. Some insights have been gained from the following two examples: tau protein and moonlighting peptides (Rodríguez et al. 2012). Tau protein, which is unfolded in its native state (Jeganathan et al. 2008), is known to change its conformation to bind to neuronal axons or form aggregates that cause neuronal diseases (Kolarva et al. 2012). In addition, it has been demonstrated that a single amino acid residue can govern the folding of tau (Margittai and Langen, 2006). Rodríguez and colleagues (2012) demonstrated that a part of proteins (in their case, peptides) govern multiple functions. From these examples, it might be said that a single protein is likely to regulate multiple functions by changing its conformation to change the exposed surface of individual domains.

Some researchers consider that moonlighting is not a special feature. Proteins can change their three-dimensional folding to change their interactions with other proteins. In association with proper proteins, the moonlighting protein can play a role in some biological events (Tompa et al. 2005, Sugase et al. 2007). These proteins are sometimes called “intrinsically unstructured proteins (IUPs)” (Dunker et al. 2001) and can be considered as a subset of moonlighting proteins, although the differences between IUPs and moonlighting proteins are under debate (Hernández et al. 2012). It may be said that changing protein structure to accommodate associated biomolecules (Sinthuvanich et al. 2012) is the molecular mechanism of moonlighting. In that case, a part of the moonlighting protein domain can be attributed to moonlighting properties, and the domain can change its conformation easily. The important question here is whether the specific amino acid sequence, which participates in a certain function exists.
Fig. 3 Glycolysis and the associated pathways

Glycolytic enzymes and their moonlighting functions

Glycolytic enzymes are conserved proteins in most biological species. They are also present in *Achaea, Mycoplasma* (free living organism with the smallest genome), cyanobacteria, and algae. Glycolytic enzymes are an important class of proteins that produce energy from carbon sources under anaerobic conditions. The glycolytic pathway is connected to and crossed with important metabolic pathways such as the pentose phosphate pathway, TCA cycle, amino acid synthesis, and lipid metabolism (Fig. 3). Thus, they are vital cellular components.

Of the 43 moonlighting proteins reported before 2005, 47% of them were previously known as glycolytic enzymes (Pancholi 2001, Sriram et al. 2005). It is known today that all glycolytic enzymes are moonlighting proteins (Table 1). The moonlighting functions of glycolytic enzymes are often related to important cellular machineries such as transcription, translation, signal transduction, cell movement, and trafficking.

### Table 1 Glycolytic enzymes and examples of their moonlighting functions

<table>
<thead>
<tr>
<th>Glycolytic enzymes</th>
<th>Genes (S. cerevisiae)</th>
<th>Moonlighting functions</th>
<th>organisms</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hexokinase</td>
<td>PKX1, PKX2, GLK1</td>
<td>orn binding</td>
<td>rat</td>
<td>Faik et al. 1982, Linden et al. 1982</td>
</tr>
<tr>
<td>Phosphoglucone isomerase</td>
<td>PG1</td>
<td>apoptosis</td>
<td>mouse</td>
<td>Mayer et al. 2004</td>
</tr>
<tr>
<td>Phosphofructokinase</td>
<td>PFK1, PFK2</td>
<td>microautophagy</td>
<td><em>Pichia pastoris</em></td>
<td>Gancedo and Flores 2008</td>
</tr>
<tr>
<td>Fructose bisphosphate aldolase</td>
<td>FBA1</td>
<td>V-ATPase assembly</td>
<td><em>B. subtilis</em> and <em>S. aureus</em></td>
<td>Connichan et al. 2009, Roux et al. 2011</td>
</tr>
<tr>
<td>Trisphosphate isomerase</td>
<td>TP1</td>
<td>adhesin</td>
<td><em>C. neoformans</em></td>
<td>Frey et al. 2009</td>
</tr>
<tr>
<td>Glyceraldehyde phosphate</td>
<td>TDP1, TDP2, TDP3</td>
<td>uracil bioglycosylation</td>
<td>human</td>
<td>Meyn-Szegel et al. 1991</td>
</tr>
<tr>
<td>Phosphoglycerate kinase</td>
<td>PGK1</td>
<td>endocytosis</td>
<td>rat</td>
<td>Robbins et al. 1995</td>
</tr>
<tr>
<td>Phosphoglycerate mutase</td>
<td>GPM1</td>
<td>RNA-binding</td>
<td>human</td>
<td>Komai et al. 1983</td>
</tr>
<tr>
<td>Enolase</td>
<td>ENO1, ENO2</td>
<td>plasmogen reductase</td>
<td><em>P. sativum</em></td>
<td>Zheng et al. 2003</td>
</tr>
<tr>
<td>Pyruvate kinase</td>
<td>CDC19, PYK2</td>
<td>prilinogen receptor</td>
<td><em>C. albicans</em></td>
<td>Leu et al. 2000</td>
</tr>
</tbody>
</table>

Moonlighting glycolytic enzymes often need to change their location to perform their moonlighting functions. For example, enolase has at least seven moonlighting functions (Table 1) both inside and outside the cell. Extracellular enolase, which is a glycolytic enzyme, is a virulence factor in *Candida albicans* and some parasites (Jong et al. 2003, Avilan et al. 2011). Enolase has been found in small vesicles outside the cell (Oliveira et al. 2010, Oliveira et al. 2010) and in the cell
wall (Edwards et al. 1999). In addition, enolase is secreted in a sequence-dependent manner (Lopez-Villar et al. 2006, Yang et al. 2011) and is present in the cell wall with no enzymatic activity, but it binds to plasminogen and helps pathogens invade (Swenerton et al. 2011). Enolase is also found in viral particles (Bechtel et al. 2005, Chertova et al. 2006, Shaw et al. 2008) and is required for transcription in Sendai virus (Ogino et al. 2001). Therefore, enolase is a therapeutic target for many diseases, including candidiasis (van Deventer et al. 1996, Capello et al. 2011). Another extracellular glycolytic enzyme, phosphoglucose isomerase, enhances the motility of tumor cells (Dobashi et al. 2006) and acts like a cytokine (Torimura et al. 2001), although it possesses no enzymatic activity outside the cell (Tsutsumi et al. 2003). However, the secretory pathway of glycolytic enzymes such as enolase and phosphoglucose isomerase remains to be revealed. This pathway appears to be unconventional because glycolytic enzymes have no known secretion signals. Therefore, in this study, we analyze the secretory pathway of glycolytic enzymes.

Conventional secretion pathways of proteins have been extensively studied using *Saccharomyces cerevisiae* (Schekman 2010). In addition, we may reveal unknown secretion pathways of proteins; however, it remains challenging because the trafficking patterns inside the organism are not completely known.

**Secretion pathways of *S. cerevisiae***

*S. cerevisiae* is a model organism for determining the secretion pathways of proteins and lipids because it has known gene sets that work in various protein transport pathways. Schekman (Novick and Schekman 1979, Novick et al. 1980, Schekman 2010), Ohsumi (Nagatogawa et al. 2009, Mizushima et al. 2011), and numerous other researchers (Bryant and Stevens 1998, Hua et al. 2002, Gall et al. 2002) have developed various temperature-sensitive and/or knockout mutants of *S. cerevisiae* to investigate protein transport pathways. The outline of *S. cerevisiae* secretion pathways is shown in Fig. 4.

Protein transport mediated by membrane cargoes is regulated by various membrane-associated proteins or protein complexes (Whyte and Munro 2002, Bröcker et al. 2010). Among the proteins involved in transport machineries, soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) proteins are the most extensively studied (Ungar and Hughson, 2003, Duman and Forte 2003, Jahn and Scheller 2006, Table 2). As shown in Table 2, 13 of 23 SNAREs are essential, and at least 9 proteins are used in more than two of the pathways described in Fig. 4. Of these, pathways 5 and 6 are considered conventional secretion pathways, while the others (17 and secretion via early endosome) are unconventional. The pathway used by unconventionally secreted moonlighting glycolytic enzymes remains unknown.
Spatial arrangement of glycolytic enzymes

Fluorescent protein tags have been used to determine the subcellular localization of proteins (Phillips 2001, Rudner and Losick 2010, Chudakov et al. 2010), especially in *S. cerevisiae*. Dr. Erin O'Shea and Dr. Jonathan Weissman at UCSF generated a collection of *S. cerevisiae* open reading frames that were tagged at the carboxy terminal using the coding sequence of *Aequorea victoria* GFP (S65T) (Huh et al. 2003). A database of GFP-fused protein localization (yeast GFP localization database, http://yeastgfp.yeastgenome.org/) is now available. In addition, many other databases for the subcellular localization of proteins are available (LOCATE, subcellular localization database for mouse and human, http://locate.imb.uq.edu.au/; eSLAB, a database of protein subcellular localization annotation for eukaryotic organisms, http://gpcr.biocomp.unibo.it/esldb/; Organelle DB, a database of organelle proteins and subcellular structures/complexes, http://organelledb.lsi.uchicago.edu/; locDB, collection of experimental annotations for the subcellular localization of proteins in human and weed, http://www.rostlab.org/services/locDB/). Apart from its property to accumulate in the nucleus to some extent (Seibel et al. 2007) and that its fluorescence intensity is affected by oxygen concentration (Yang et al. 1996, Takahashi et al. 2006), GFP is useful
and is one of the frequently used fluorescent proteins. Accumulation, aggregation, and association of proteins inside the cell often indicate some cellular machineries or protein functions (Kanda et al. 1998, Bence et al. 2001, Tilsner and Oparka 2010). Therefore, protein localization in response to certain stimuli has been extensively researched to discover novel cellular machineries (Sakai et al. 1997, Dastoor and Dreyer 2001, An et al. 2008, Narayanaswamy et al. 2009, Noree et al. 2010).

Spatial rearrangement of moonlighting proteins, including glycolytic enzymes, is highly important for their various functions. In several organisms and cells, some glycolytic enzymes have been reported to associate with the cytoskeleton (Masters 1984, Stephan et al. 1986), erythrocyte membrane (Campanella et al. 2005), or muscle (Brooks and Storey 1988), or to associate with each other (Mowbray and Moses 1976, Anderson et al. 1995, Mazzola and Sirover 2003). In a few species of protozoa, including Trypanosoma brucei, glycolytic enzymes are contained in a membrane-enclosed organelle called glycosome (Hannaert and Michels 1994, Bakker et al. 2000). Association of glycolytic enzymes is believed to facilitate metabolism (Beeckmans et al. 1990, Amar et al. 2008). In addition, changes in the localization of glycolytic enzymes suggest other moonlighting functions (Dastoor and Dreyer 2001, Decker and Wickner 2006).

The intracellular assembly of glycolytic enzymes has been observed in mammalian cells; one of the glycolytic enzymes, i.e., GAPDH conjugated with GFP, was found to form fluorescent foci under hypoxia (Agbor et al. 2011). Agbor and colleagues (2011) demonstrated that the spatial rearrangement was dependent on modification by small ubiquitin-like modifier (SUMOylation). However, its function and sensing machineries involved in the initiation of spatial reorganization of the glycolytic enzyme under hypoxia remain known. It is important to determine the location of the foci because GAPDH has been reported to translocate into the nucleus under hypoxia (Stannard et al. 2004). Moreover, according to the S. cerevisiae database (yeast GFP localization database, http://yeastgfp.yeastgenome.org/), subcellular localization of glycolytic enzymes fused with GFP (GFP clones, Invitrogen) is uniform in the cytoplasm. Therefore, it is uncertain whether glycolytic enzymes change their localization in response to hypoxia, especially in yeast cells. When the spatial rearrangement of glycolytic enzymes occurs under hypoxia, the relocalization of enzymes may affect cell physiology.
<table>
<thead>
<tr>
<th>Pathway</th>
<th>SNARE protein- coding genes</th>
<th>Essential / or nonessential</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 ER to Golgi</td>
<td>SED5</td>
<td>essential</td>
<td>cis-Golgi t-SNARE syntaxin required for vesicular transport between the ER and the Golgi complex, binds at least 9 SNARE proteins</td>
</tr>
<tr>
<td></td>
<td>YKT6</td>
<td>essential</td>
<td>Vesicle membrane protein (v-SNARE), with acyltransferase activity; involved in trafficking to and within the Golgi, endocytic trafficking to the vacuole, and vacuolar fusion; membrane localization due to prenylation at the carboxy-terminus</td>
</tr>
<tr>
<td></td>
<td>SEC22</td>
<td>nonessential</td>
<td>R-SNARE protein; assembles into SNARE complex with Bet1p, Bos1p and Sed5p; cycles between the ER and Golgi complex; involved in anterograde and retrograde transport between the ER and Golgi; synaptobrevin homolog</td>
</tr>
<tr>
<td></td>
<td>BOS1</td>
<td>essential</td>
<td>v-SNARE (vesicle specific SNAP receptor), localized to the endoplasmic reticulum membrane and necessary for vesicular transport from the ER to the Golgi</td>
</tr>
<tr>
<td></td>
<td>BET1</td>
<td>essential</td>
<td>Type II membrane protein required for vesicular transport between the endoplasmic reticulum and Golgi complex; v-SNARE with similarity to synaptobrevins</td>
</tr>
<tr>
<td>2 Golgi to ER</td>
<td>SEC22</td>
<td>nonessential</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>UFE1</td>
<td>essential</td>
<td>t-SNARE required for retrograde vesicular traffic and homotypic ER membrane fusion; forms a complex with the SNAREs Sec22p, Sec20p and Ufe1p to mediate fusion of Golgi-derived vesicles at the ER</td>
</tr>
<tr>
<td></td>
<td>SEC20</td>
<td>essential</td>
<td>Membrane glycoprotein v-SNARE involved in retrograde transport from the Golgi to the ER; required for N- and O-glycosylation in the Golgi but not in the ER; interacts with the Ds1p complex through Tip20p</td>
</tr>
<tr>
<td></td>
<td>USE1</td>
<td>essential</td>
<td>Essential SNARE protein localized to the ER, involved in retrograde traffic from the Golgi to the ER; forms a complex with the SNAREs Sec22p, Sec20p and Ufe1p</td>
</tr>
<tr>
<td></td>
<td>GOS1</td>
<td>nonessential</td>
<td>v-SNARE protein involved in Golgi transport, homolog of the mammalian protein Gos-28/GS28</td>
</tr>
<tr>
<td></td>
<td>YKT6</td>
<td>essential</td>
<td>Vesicle membrane protein (v-SNARE), with acyltransferase activity; involved in trafficking to and within the Golgi, endocytic trafficking to the vacuole, and vacuolar fusion; membrane localization due to prenylation at the carboxy-terminus</td>
</tr>
<tr>
<td>3 Golgi (cis to TGN)</td>
<td>GOS1</td>
<td>nonessential</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>SFT1</td>
<td>essential</td>
<td>Intra-Golgi v-SNARE, required for transport of proteins between an early and a later Golgi compartment</td>
</tr>
<tr>
<td>4 Golgi (TGN to cis)</td>
<td>YKT6</td>
<td>essential</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>SED5</td>
<td>essential</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>VT11</td>
<td>essential</td>
<td>Protein involved in cis-Golgi membrane traffic; v-SNARE that interacts with two t-SNAREs, Sed5p and Pep12p; required for multiple vacuolar sorting pathways</td>
</tr>
<tr>
<td></td>
<td>SLT1</td>
<td>essential</td>
<td>Essential SNARE protein localized to the ER, involved in retrograde traffic from the Golgi to the ER; forms a complex with the SNAREs Sec22p, Sec20p and Ufe1p</td>
</tr>
<tr>
<td>5 TGN to CM (light)</td>
<td>SSO1/2</td>
<td>nonessential</td>
<td>Plasma membrane t-SNAREs involved in fusion of secretory vesicles at the plasma membrane</td>
</tr>
<tr>
<td></td>
<td>SNG1/2</td>
<td>nonessential</td>
<td>Vesicle membrane receptor protein (v-SNARE); involved in the fusion between Golgi-derived secretory vesicles with the plasma membrane; proposed to be involved in endocytosis, member of the synaptobrevin/VAMP family of R-type v-SNARE proteins</td>
</tr>
</tbody>
</table>
Table 2 SNARE proteins involved in secretion pathway (continued)

<table>
<thead>
<tr>
<th>Pathway</th>
<th>Protein</th>
<th>Activity</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>TGN to CM (light)</td>
<td>SEC9</td>
<td>essential</td>
<td>t-SNARE protein important for fusion of secretory vesicles with the plasma membrane; similar to but not functionally redundant with Spc20p; SNAP-25 homolog</td>
</tr>
<tr>
<td>TGN to CM (heavy)</td>
<td>YKT6</td>
<td>essential</td>
<td>-</td>
</tr>
<tr>
<td>TGN to V</td>
<td>VAM3</td>
<td>nonessential</td>
<td>Syntaxin-like vacuolar t-SNARE that functions with Vam7p in vacuolar protein trafficking; mediates docking/fusion of late transport intermediates with the vacuole; has an acidic di-leucine sorting signal and C-terminal transmembrane region</td>
</tr>
<tr>
<td></td>
<td>VTI1</td>
<td>essential</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>VAM7</td>
<td>nonessential</td>
<td>Vacuolar SNARE protein that functions with Vam3p in vacuolar protein trafficking; has an N-terminal PX domain (phosphoinositide-binding module) that binds PtdIns-3-P and mediates membrane binding; SNAP-25 homolog</td>
</tr>
<tr>
<td></td>
<td>NYV1</td>
<td>nonessential</td>
<td>V-SNARE component of the vacuolar SNARE complex involved in vesicle fusion; inhibits ATP-dependent Ca(2+) transport activity of Pmc1p in the vacuolar membrane</td>
</tr>
<tr>
<td>TGN to EE</td>
<td>SNC1/2</td>
<td>nonessential</td>
<td>-</td>
</tr>
<tr>
<td>EE to TGN</td>
<td>TGL2</td>
<td>nonessential</td>
<td>Syntaxin-like t-SNARE that forms a complex with Tgl1p and Vt1p and mediates fusion of endosome-derived vesicles with the late Golgi; binds Vps45p, which prevents Tgl2p degradation and also facilitates t-SNARE complex formation; homologous to mammalian SNARE protein syntaxin 15 (Sx15)</td>
</tr>
<tr>
<td></td>
<td>VTI1</td>
<td>essential</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>TGL1</td>
<td>essential</td>
<td>Essential t-SNARE that forms a complex with Tgl2p and Vt1p and mediates fusion of endosome-derived vesicles with the late Golgi; binds the docking complex VFT(Vps fifty-three) through interaction with Vps51p</td>
</tr>
<tr>
<td></td>
<td>YKT6</td>
<td>essential</td>
<td>-</td>
</tr>
<tr>
<td>TGN to LE</td>
<td>PEP12</td>
<td>nonessential</td>
<td>Target membrane receptor (t-SNARE) for vesicular intermediates traveling between the Golgi apparatus and the vacuole; controls entry of biosynthetic, endocytic, and retrograde traffic into the prevacuolar compartment; syntaxin</td>
</tr>
<tr>
<td></td>
<td>VTI1</td>
<td>essential</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>SYN8</td>
<td>nonessential</td>
<td>Endosomal SNARE related to mammalian syntaxin 8</td>
</tr>
<tr>
<td>CM to EE</td>
<td>SYN8</td>
<td>nonessential</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>SNC1/2</td>
<td>nonessential</td>
<td>-</td>
</tr>
<tr>
<td>LE to V</td>
<td>VTI1</td>
<td>essential</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>VAM7</td>
<td>nonessential</td>
<td>-</td>
</tr>
</tbody>
</table>

Cell physiology under hypoxia

Hypoxia is a condition in which the cell is deprived of adequate oxygen supply. Many studies define hypoxia at ≤2 mg/L of dissolved oxygen (DO) in an aqueous environment (Eby et al. 2002, Buzzelli et al. 2002). In cultured mammalian cells, 1% atmospheric oxygen is regarded to be a hypoxic state, while 21% is regarded to be the normal oxygen concentration (normoxia) (Hagen et al. 2003, Frezza et al. 2011). A hypoxic state for mammalian cells often occurs in vivo when the oxygen supply is limited (Denko 2008). Hypoxia is reported to correlate with many diseases including heart attack, cancer, and stroke (Lyer et al. 1998). Some tumor cells are known to respond to hypoxia and obtain increased metastatic activity (Zhong et al. 1999), radiation resistance (Eyler and Rich 2008), and drug resistance (Teicher 1994). Baker’s yeast, *S. cerevisiae* is also well known to respond to hypoxia during fermentation (Simeonidis et al. 2010). When sufficient amounts of nutrients are supplied, *S. cerevisiae* produces CO$_2$ in metabolic processes, which decreases the oxygen concentration in the medium (Rosenfeld et al. 2003). The hypoxic responses of yeast cells have attracted attention because researchers have proved that these responses have some roles in infection by pathogenic fungi including *C. albicans* (Grahl and Cramer, 2010) and *Aspergillus fumigatus* (Grahl et al. 2011, Filler and Rhodes, 2012).

The hypoxic responses of mammalian cells and yeasts are common to some extent (Fig. 5). Because molecular oxygen is required for heme and sterol biosynthesis, the production of these molecules is reduced under hypoxia (Hickman et al. 2011, Siso et al. 2012). In addition, oxygen deprivation triggers the release of reactive oxygen species (ROS) from mitochondria (Chandel et al. 1998, Chandel et al. 2000, Blokhina et al. 2003, Guzy et al. 2005, Bell et al. 2007, Murphy 2009) by unknown mechanisms (Guzy and Schumacker 2006). These primary hypoxic responses trigger the following secondary responses. In mammalian cells, cytosolic ROS stabilize hypoxia-inducible factor 1α (HIF-1α) (Guzy and Schumacker 2006), which is a major regulator for the hypoxic response. ROS (Gillespie et al. 2009, Ruchko et al., 2009, Poyton et al. 2009, Gillespie et al. 2010), and HIF-1α (Ortiz-Barahona et al. 2010, Tanimoto et al. 2010, Schödel et al. 2011, Liu et al. 2012) oxidizes or binds several specific bases in hypoxia-responsive elements (HRE). Genes containing HRE in their promoters include those that encode aldolase, enolase, and lactate dehydrogenase (Semenza et al. 1996). In mammalian cells, transcription of PKM2, a gene that encodes one of the glycolytic enzymes, is activated by HIF-1α (Luo et al. 2011). Interestingly, Pkm2p interacts directly with the HIF-1α subunit and acts as a coactivator (Luo et al. 2011). In addition to HRE oxidation, mitochondria-generated ROS trigger AMP-activated protein kinase signaling (Jung et al. 2008, Emerling et al. 2009, Mungai et al. 2011, Kim et al. 2011) through several reaction steps (Mungai et al. 2011). Yeast cells have no HIF-1α homologs (Rytkönen and Storz 2011); however, yeast has HRE clusters in the promoters of *TDH2, ALD6*, and genes involved in amino acid metabolism (Ferreira et al. 2007). It is also reported that hexose transporters are affected under a hypoxic condition,
accelerating the uptake of extracellular hexoses (Rintala et al. 2008). Because of the resemblance of responses to hypoxia between *S. cerevisiae* and mammalian cells, some researchers regard *S. cerevisiae* as one of the model organisms for studying a hypoxic response (Netzar and Breitenbach 2010). Mitochondrial ROS production can also be measured in yeast cells. Using dihydroethidium and MitoSOX Red, cellular and mitochondria-specific reactive oxygen can be measured *in vivo* (Quaranta et al. 2011). 2′, 7′-dichlorofluorescin diacetate can also be used as a cytosolic indicator of ROS (Gomes et al. 2005, Bonini et al. 2006, Al-Mehdi et al. 2012).

Hypoxic response mechanisms have been extensively studied by culturing yeast cells in a media depleted in oxygen by sparging with N₂ (Kwast et al. 2002, Lai et al. 2008). Kwast and colleagues (2002) have shown that N₂-induced hypoxia triggers global changes in metabolic gene induction. Interestingly, these two researches do not report enolase gene induction, in contrast to that in mammalian cells (Kwast et al. 2002, Lai et al. 2008). In *S. cerevisiae*, a decrease in heme and sterol levels induces the activation of transcription by Upc2p, while a decrease in only heme levels inhibits Rox1p and Mot3p to repress hypoxic genes, thus inducing hypoxia-responsive genes (Grahl and Cramer, 2010). The connection between sterol- and heme-regulated responses to hypoxia, and their correlation with mitochondrial ROS production have not been described.

![Outline of similar hypoxic responses in mammalian and yeast cells](image)

**Fig. 5 Outline of similar hypoxic responses in mammalian and yeast cells**

In response to hypoxia, cultured mammalian cells produce large amounts of lactate, alanine (Brecht and Groot 1994, Chateil et al. 2001), and acetate. On the other hand, *S. cerevisiae* cells grown under hypoxic conditions are known to produce ethanol, glycerol, succinic acid, and alanine (Chico et al. 1978, Gleason et al. 2011) as end products of glycolysis. These changes in metabolites, especially overproduction of alanine under hypoxia, are also known in flies (Feala et al. 2007) and
plants (Rocha et al. 2010). In rat heart, aspartate production is significantly increased under hypoxia relative to normoxia (Rumsey et al. 1999). Alanine, aspartate, and other amino acids are considered to protect cells from hypoxic injury (Weinberg et al. 1990, Brecht and Groot 1994). In yeasts, conversion of pyruvate to oxaloacetate and aspartate is a part of gluconeogenesis, which enables yeast cells to grow on non-sugar carbon sources such as ethanol, glycerol, or peptone (Foy and Bhattacharjee 1977, Eschrich et al. 2002).

In case of gluconeogenesis in yeast, acetyl-CoA carboxylase produces malonyl-CoA under regulation by SNF1, which is a yeast functional homolog of mammalian AMP kinase (Woods et al. 1994). Malonyl-CoA is the first precursor of long fatty acids (Fig. 6). Without acetyl-CoA carboxylase, yeasts need fatty acids to survive and arrest the G2/M phase of the cell cycle (Al-Feel et al. 2003). Acetyl-CoA carboxylase is also vital in mammalian cells, as RNAi of acetyl-CoA carboxylase inhibits the growth of prostate cancer cells and mouse embryos (Abu-Elheiga et al. 2005, Brusselmans et al. 2005).

![Fig. 6 Fatty acid synthesis from pyruvate in S. cerevisiae](image)

There had been several reports demonstrating that cobalt and other metal ions induce cellular responses, which resemble the hypoxic response. However, reports also suggest that there are some differences between these two stimuli. For example, overproduction of alanine is observed under hypoxia but not in the presence of cobalt (Gleason et al. 2011). In addition, ROS generation by hypoxia and by CoCl$_2$ addition is differently inhibited by adding mitochondria-inhibiting agents to mammalian cells (Chandel et al. 2000).

Although the role of the spatial relocalization of glycolytic enzymes under hypoxia is not revealed, there is a report suggesting the importance of spatial localization of cellular components. Recently, Al-Mehdi and colleagues (2012) have revealed that mitochondria localize near the nucleus.
under hypoxia to translocate ROS into the nucleus and oxidize guanine nucleotides of specific promoter DNA sequences in order to induce the expression of the vascular endothelial growth factor-encoding gene \((VFGF)\) (Murphy 2012). The results suggest that regulating intracellular localization of mitochondria has an important role in the hypoxic response. If glycolytic enzymes change their localization in the cell, the role this relocation plays in cellular metabolism and the mechanisms that regulate this translocation should be investigated.

**Culture instruments for cultivation of yeast cells**

Suitable culture vials are needed to study hypoxia in yeast cells. A novel culture device, which can separate and co-cultivate different types of cells at the same time, is needed to investigate unknown functions of unconventionally secreted proteins.

Because yeast cells experience a hypoxic environment during fermentation, vials for fermentation can be used to investigate their hypoxic responses. Glass vials have been developed by Matsumoto et al. (2002) for laboratory-scale fermentation. A small pump can be used to create normoxia (sufficient oxygen concentration) in these vials.

Several different culture vials, including Millicell culture inserts (Millipore, Germany), IdMOC (Kurabo, Osaka, Japan), and Alvetex (TaKaRa Bio, Otsu, Japan), have been developed for the investigation of intercellular proteins. Because these chambers developed are for mammalian cells, only a small volume of microbial cells can be cultured using these chambers. These chambers can be used for co-cultivation of different cells, but first, a model system to investigate the intercellular function of extracellular proteins should be constructed. Following which, large-scale culture vials for separated co-cultivation should be developed.

To determine the molecular machineries that enable proteins to perform moonlighting functions, investigating the mechanism regulating the localization of moonlighting proteins is a plausible approach. In this regard, the following questions arise:

- Is there a specific amino acid sequence that participates in certain localizations?
- Through which transporting pathway is the change in localization achieved?
- By which cellular mechanism or sensing pathway is the change in localization regulated?
- Does the change in localization correlate with cell physiology?

These issues were addressed in this study using the moonlighting glycolytic enzyme, enolase, as a model.
REFERENCES


13. Bell EL, Klimova TA, Eisenbart J, Moraes CT, Murphy MP, Budinger GR, Chandel NS (2007) The Qo site of the mitochondrial complex III is required for the transduction of


93:1259–1269.


CHAPTER I
Searching for secretory pathway of enolase and discovery of enolase foci-forming region

Introduction
Glycolytic enzymes play various roles inside and outside the cell (Tristan et al. 2011). Although they are cytosolic proteins, numerous large-scale analyses have revealed their extracellular existence, in both unicellular and multicellular organisms (Lamonica et al. 2005, Nombela et al. 2006, Chiellini et al. 2008, Oliveira et al. 2010, Oliveira et al. 2010, Shinya et al. 2010). Many glycolytic enzymes have been reported to play roles in important cellular processes such as signal transduction and surface binding (Sriram et al. 2005, Makhina et al. 2009, Ghosh and Jacobs-Lorena 2011, Renigunta et al. 2011). For example, extracellular enolase, which is a glycolytic enzyme, is a virulence factor in Candida albicans and other parasites (Jong et al. 2003, Avilan et al. 2011). Enolase has been found in small vesicles outside the cell (Oliveira et al. 2010, Oliveira et al. 2010) and in the cell wall (Edwards et al. 1999). In addition, enolase is secreted in a sequence-dependent manner (Lopez-Villar et al. 2006, Yang et al. 2011), and presents in the cell wall with no enzymatic activity, but binds to plasminogen and helps the pathogen invade (Swenerton et al. 2011). Enolase is also found in viral particles (Bechtel et al. 2005, Chertova et al. 2006, Shaw et al. 2008), and is required for transcription of the Sendai virus (Ogino et al. 2001). Therefore, enolase is a therapeutic target for many diseases, including candidiasis (van Deventer et al. 1996, Capello et al. 2011). Another extracellular glycolytic enzyme, phosphoglucose isomerase, enhances the motility of tumor cells (Dobashi et al. 2006) and performs like a cytokine (Torimura et al. 2001), although it possesses no enzymatic activity outside the cell (Tsutsumi et al. 2003). However, the secretory pathway of glycolytic enzymes such as enolase and phosphoglucose isomerase remains to be revealed. This pathway appears to be unconventional because glycolytic enzymes have no known secretion signals. Therefore, in this study, I analyzed the secretory pathway of glycolytic enzymes.

A number of secreted proteins without known secretion signals have been found (Kinseth et al. 2007), and several unconventional secretory pathways have been discovered and suggested (Duran et al. 2010, Manjithaya et al. 2010, Nickel and Rabouille 2009). Recently, Duran and coworkers identified the novel unconventional secretory pathway of the Acb1 protein (Duran et al. 2010). The budding yeast Saccharomyces cerevisiae is a useful organism to identify previously unknown secretory pathways, because it is a commonly used and well-understood model for studying cellular processes (Schekman 2010).

Two popular methods can be used to detect cellular secretion, namely, secretome analysis and glucoamylase assay (Innis et al. 1985). Although these methods are highly informative and convenient, three major problems arise when using them to detect unknown secretory pathways. First, because proteome analysis targets naturally produced proteins, the proportion of each protein
varies. Therefore, the secretory abilities of different proteins are incommensurable, and detecting leakage is inevitable. Second, the glucoamylase assay cannot detect changes in the size of proteins. Therefore, this method can miss the processing of proteins during secretion, which is important for the prediction of the secretory pathway. Third, neither method can visually trace the intracellular secretory pathway. Therefore, it is important to be cautious with the information obtained by these methods and investigate all the possible pathways.

Previously, Morisaka and colleagues have developed a novel two-dimensional high-performance liquid chromatography (2D-HPLC)-based method that detects proteins on the living cell surface (Morisaka et al. 2012). Using this method, an overview of the proteins on the outside of the cell can be gained. In addition, glycolytic enzymes suitable for secretion analyses can be selected. In this study, I utilized enhanced green fluorescence protein conjugated with FLAG-tag (EGFP-FLAG)-tagged glycolytic enzymes to analyze the secretory pathway of glycolytic enzymes. Western blot analysis enabled detection of the secreted proteins in the culture media. Moreover, the use of plasmid-based protein expression facilitated uniform protein levels and analysis of the secreted proteins. Moreover, the secretory pathway was visualized and assessed with the aid of the conjugated fluorescent proteins (Hirschberg and Lippincott-Schwartz 1999, Huang and Shusta 2005).

Materials and methods

Strains and media

Escherichia coli DH5α (F−, Φ80lacZΔM15, Δ(lacZYA-argF)U169, deoR, recA1, endA1, hsdR17(k-, mK+), phoA, supE44, λ−, thi-1, gyrA96, relA1) strain was used for host cells in the cloning experiments. The temperature-sensitive sec23-1 strain RSY282 (MATα, leu2Δ, ura3Δ, sec23-1) was kindly provided by Dr. Randy Schekman (Department of Molecular and Cell Biology and Howard Hughes Medical Institute, University of California at Berkeley). The yeast strain BY4741 (MATa, his3Δ1, leu2Δ, met15Δ, ura3Δ), and the derived deletion strains of SED1 (sed1Δ), SSO1 (sso1Δ), SSO2 (sso2Δ), SEC22 (sec22Δ), SNC2 (snc2Δ), TLG2 (tlg2Δ), BTN2 (btn2Δ), PEP12 (pep12Δ), VPS31 (vps51Δ), GOS1 (gos1Δ), ATG1 (atg1Δ), ATG8 (atg8Δ), ATG11 (atg11Δ), ATG17 (atg17Δ), ATG20 (atg20Δ), VAM3 (vam3Δ), and GRHI (grh1Δ) were purchased from EUROSCARF (Frankfurt, Germany). The yeast GFP clones (Invitrogen, Carlsbad, CA, USA) with GFP-tagged endogenous proteins (Pma1p, Nup84p, Mae1p, Chs5p, Snf7p, Vrg4p, Pex11p, and Sec13p) and HIS3 marker in the parent BY4741 strain were used to determine the localization of proteins. E. coli was grown in lysogeny broth (LB) (1% (w/v) tryptone, 0.5% (w/v) yeast extract, 0.5% (w/v) sodium chloride, and 100 ng/mL ampicillin). The yeast cells were grown in yeast extract peptone dextrose (YPD) medium (1% (w/v) yeast extract, 2% (w/v) polypeptone, and 2% (w/v) glucose), SD+HM medium (0.67% (w/v) yeast nitrogen base without amino acids, 2% (w/v) glucose, 0.002%
L-histidine-HCl, and 0.003% L-methionine), SDC+HM medium (0.67% (w/v) yeast nitrogen base without amino acids, 2% (w/v) glucose, 0.002% L-histidine-HCl, 0.003% L-methionine, 2% casamino acids (BD, Franklin Lakes, NJ), and 2% (w/v) agar), SC+ML medium (0.67% (w/v) yeast nitrogen base without amino acids, 2% (w/v) glucose, 0.003% L-methionine, 0.003% L-leucine, 0.13% SD multiple drop Out (-Ade, -His, -Leu, -Lys, -Trp, -Ura, Funakoshi Co., Ltd., Tokyo, Japan), 2% (w/v) agar), SD+ML medium (0.67% (w/v) yeast nitrogen base without amino acids, 2% (w/v) glucose, 0.003% L-methionine, 0.003% L-leucine), or SDC+ML medium (SD+ML supplemented with 2% casamino acids).

Construction of *S. cerevisiae* expression plasmids

The plasmids were constructed using a conventional PCR-based method and our novel PCR-free method (one-step construction method for plasmids (OSCoM-P); Fig. 1). In addition, iProof DNA polymerase (Bio-Rad, Richmond, CA, USA), KOD-plus-DNA polymerase (Toyobo, Osaka, Japan), KOD-plus-Neo-DNA polymerase (Toyobo), Ligation High (Toyobo), and synthetic oligonucleotides (Japan Bio Services, Saitama, Japan) were used. All primers used in this study are shown in Table 1.

The plasmids for the internal production of the recombinant proteins were constructed from pULSG1 (Matsui et al. 2009). The primers coding the ATG codon were mixed with the pULSG1 digest and inserted using the *EcoR* I and *Xho* I sites by OSCoM-P (Fig. 1); the resulting plasmid was named pUL-ATG-EGFP. The section of pUL-ATG-EGFP including the *GAPDH* promoter, the terminator, the FLAG-tag (DYKDDDDK; 21), and the EGFP sequence was amplified and added to the *BamH* I and *Not* I sites by PCR using the primers *GAPDH* promoter-F and *GAPDH* terminator-R, and inserted into the *BamH* I–*Not* I section of pRS423 (47, from ATCC); the resulting plasmid was named pRS423-ATG-EGFP. For constructing the plasmid pULGI2, OSCoM-P was also performed. Oligonucleotide fragments with several restriction sites were inserted into pULSG1 by using the *EcoR* I and *Xho* I sites. The plasmids for the internal expression of the glycolytic enzymes conjugated with EGFP-FLAG were constructed as follows. The yeast genomic DNA was extracted and purified from the *S. cerevisiae* BY4741 strain, and each gene coding a glycolytic enzyme was cloned using the appropriate primer set (Table 1). The fragments were digested and inserted into pULGI2 by using the *BamH* I and *Xho* I sites or the *BamH* I and *Sac* I sites. The internal expression vector without EGFP was constructed from pULSG1C (Matsui et al. 2009) and pWGP3 (Takahashi et al. 2001). The multi-cloning site followed by the *GAPDH* terminator sequence was amplified from pWGP3 and inserted into pULSG1C by using the *Sac* I and *Kpn* I sites; the resulting plasmid was named pULI1. For the construction of the plasmid for the intercellular production of enolase-EGFP-FLAG with the N-terminal peptide sequence (HA-tag), the HA-tag sequence was inserted into pULGI2 by using OSCoM; the resultant plasmid was named pULGI2-HA. The *ENO2* coding sequence from pULGI2-ENO2 was inserted into pULGI2-HA, and the resultant plasmid was
named pULGI2-HA-ENO2. For the construction of plasmids to produce the red-fluorescent proteins, the *Discosoma* red fluorescent protein (DsRED) monomer with *EcoR* I and *Xho* I sites at the N-terminus and *Sal* I at the C-terminus was cloned from pKRD4 (Kuroda et al. 2009). The amplified fragments were digested with *EcoR* I and *Sal* I, and then inserted into the same site of pULSG1; the resultant plasmid was named pUL-ATG-DsRED. For production of the enolase fragments fused with EGFP or DsRED, amplified fragments were digested and inserted into pULSG1 or pUL-ATG-DsRED by using the *EcoR* I and *Xho* I sites (see Table 1). Plasmids for production of Tlg2p (p413-ADH-TLG2) were constructed as follows: *TLG2*-coding sequence was cloned from the genomic DNA extracted from *S.cerevisiae* BY4741 and inserted into MCS of p413-ADH (ATCC 87370) using *EcoR* I and *Xho* I sites. The plasmid construction was confirmed by DNA sequencing performed using a BigDye Terminator v3.1 cycle sequencing kit and an ABI PRISM 3100 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA).

![Fig. 1 Schematic illustration of the one-step construction method for plasmids (OSCoM-P)](image)

The digested linear fragments of the plasmids were ligated with the designed primers at a dry weight ratio of 1:1–1:10 (linear plasmid:each primer). The reaction solution was directly transformed into *E. coli* DH5α competent cells (Toyobo). The purchased oligonucleotides were dissolved in dH2O at 10 ng/mL before use. TE buffer was not used because OSCoM-P was severely inhibited by the presence of TE buffer (data not shown). Maximum length of fragments to be inserted into plasmids using OSCoM-P is 45 bp (data not shown).

**Production of recombinant proteins in yeast cells**

The yeast cells were transformed with plasmids by using a Frozen-EZ Yeast Transformation II™ kit (Zymo Research, Orange, CA, USA) and grown on SDC+HM agar plates. The transformants were
selected as single colonies and inoculated into 10 mL of SD+HM medium for pre-cultivation at 25°C with shaking. At the late-log phase, the pre-culture was subcultured into 10 mL (for secretion analysis of the sec23-1 strains) or 25 mL of the same medium to obtain an optical density at 600 nm (OD\textsubscript{600}) of 0.01 (for secretion analysis of the glycolytic enzymes) or 0.3. The cells were cultivated at 25°C for 26 h (for secretion analysis of the glycolytic enzymes) or 4 h with shaking until they reached an OD\textsubscript{600} of 0.9–1.1 or 0.5. Genotypes of knockout strains were checked by colony PCR. For secretion analysis of plasmid co-transformed strains, plasmids for internal overexpression of EGFP-FLAG-conjugated proteins (pUL-X) were co-transformed with p413-plasmids into BY4741\textsuperscript{wt} and \textit{ΔTLG2} strains. Transformants were grown on SC+ML agar medium. Single colonies were picked up and re-cultivated on the same medium, and then used for secretion analysis. Transformants were pre-cultivated in 10 mL of SDC+ML media at 25°C for 26 h with shaking. Cells were washed with fresh media SD+ML and inoculated into 25 mL of SD+ML media. The cells were cultivated at 25°C for 4 h with shaking until they reached an OD\textsubscript{600} of 0.5.

**Identification of noncovalently bound cell surface proteins of living cells**

The budding yeast BY4741 sed1\textsuperscript{Δ} strain transformed with the plasmids pRS423-ATG-EGFP and pKRD4 (Kuroda et al. 2009) was grown in SDC+HM media. The noncovalently bound cell surface proteins extracted from living yeast cells by using CHAPS were separated by using a 2D-HPLC system optimized for protein separation (34). The fractionated proteins were lyophilized using a Labconco vacuum centrifuge (Labconco, MO, USA) and solubilized in 50 mM ammonium hydrogen carbonate. The collected proteins were reduced with 50 mM DTT for 30 min at 60°C and alkylated with 500 mM iodoacetamide for 45 min at room temperature. The alkylated proteins were digested by trypsin (sequencing grade modified trypsin; Promega Corp., WI, USA) for 12 h at 37°C for protein identification by mass spectrometry using a Prominence nanoflow system (Shimadzu, Kyoto, Japan) and an LTQ Velos linear ion trap mass spectrometer (Thermo Scientific Inc., Bremen, Germany). The proteolytic digests were separated by reversed-phase chromatography using a packed tip column (NTCC-360, 150 mm × 100 μm I.D.; Nikyo Technos, Tokyo, Japan) at a flow rate of 500 nL/min. The gradient was provided by changing the mixing ratio of the 2 eluents (A, 0.1% (v/v) formic acid and B, acetonitrile containing 0.1% (v/v) formic acid). The gradient was started with 5% B, increased to 45% B for 60 min, further increased to 95% B to wash the column, and then returned to the initial condition and held for re-equilibration. For data-dependent acquisition of mass spectrometry detection, the method was set to automatically analyze the top 3 most intense ions observed in the mass spectrometry scan. An ESI voltage of 1.9 kV was directly applied to the flow using a microtee. The ion transfer tube temperature on the LTQ Velos ion trap was set to 300°C. The experiments were independently repeated twice. Protein identification was performed using the combined tandem mass spectrometry data and the Protein Discoverer software (Thermo Scientific).
The results were compared to the *Saccharomyces* Genome Database (SGD; http://www.yeastgenome.org) and filtered at a q-value of ≤0.05 corresponding to 5% false discovery rate (FDR) on a spectral level, and the identified proteins contained >2 peptide fragments.

**Preparation of extracellular and intracellular proteins**
The detection was performed as follows. The culture media (25 mL) was centrifuged at 900 g for 10 min at 4°C to remove cells. Following this, the culture media were filtered through a 0.2-μm Acrodisc syringe filter (PALL Corporation, MI, USA) and concentrated by ultrafiltration (YM-10 filter for pUL11, pULSG1C, pUL-ATG-EGFP, pUL-eno(1–17), pUL-eno(1–28), and pUL-eno(1–30), and a YM-30 filter for the others; Amicon, Millipore, Millford, MA, USA). After washing thrice with 4 volumes of 20 mM Tris-HCl (pH 7.8), the concentrated proteins were frozen and lyophilized. The proteins were then suspended with 15 μL (for secretion analysis of the glycolytic enzymes) or 30 μL of loading buffer and analyzed by SDS-PAGE. The cells were suspended with 500 μL of 20 mM Tris-HCl (pH 7.8) containing 0.1% SDS. After homogenization at 4,000 rpm for 20 sec using glass beads (GB-05, diameter 0.5 mm; TOMY, Tokyo, Japan) and Bead Smash 12 (Wakenyaku, Kyoto, Japan), the sample solutions were centrifuged at 9,700 g for 5 min. Aliquots (5 μL) of the supernatants were suspended with 5 μL of 2× loading buffer and analyzed by SDS-PAGE.

**Inhibition of conventional secretion by using the sec23-1 strain**
After pre-culture in SD+HM medium, the cells were washed with fresh media and inoculated into fresh 10 mL of the same media to obtain an OD₆₀₀ of 0.3, and incubated at 25 or 37°C with shaking. After 4 h, the culture media was filtered and concentrated. Following measurement of the protein concentration, the solution was lyophilized and suspended in 10 μL of loading buffer.

**SDS-PAGE**
SDS-PAGE was conducted according to the previously described method (Laemmli, 1970) by using a continuous polyacrylamide gel (5%–20%, 120 × 100 mm, e-PAGEL; Atto, Tokyo, Japan). The samples were heated in the loading buffer at 100°C for 3 min, centrifuged at 21,900 g at 4°C for 5 min to remove the debris, and loaded. As an external standard, the FLAG-protein (48-kDa cleavage control protein; Novagen, Inc., WI, USA) was used.

**Western blotting**
After transfer to a nitrocellulose membrane (0.45 μm, pore size) by using trans-blot transfer medium (Bio-Rad), western blot analysis was performed using an anti-FLAG M2 antibody conjugated with HRP (Sigma). The loading control Pgi1p was detected using the rabbit anti-baker’s yeast Pgi1p (Acris Antibodies GmbH, Hiddenhausen, Germany) and an anti-rabbit antibody conjugated to HRP.
(GE Healthcare, UK, Ltd., Buckinghamshire, UK). The detection was enhanced by using the Can Get Signal Immunoreaction Enhancer solution (Toyobo). After detection, the antibodies were removed using a stripping agent (WB Stripping solution; Nacalai), and the membranes were blocked and reprobed using an anti-FLAG M2 antibody conjugated to HRP (Sigma). The chemiluminescence was detected using ECL Plus™ antibody conjugated to HRP (GE Healthcare). The membranes treated with the detection reagent were exposed to Amersham Hyperfilm ECL (GE Healthcare) and developed using Rendol and Renfix (Fujifilm, Kanagawa, Japan) to detect the secreted glycolytic enzymes and enolase fragments. Other data were taken by using the ImageQuant LAS 4000 mini system (GE Healthcare). Gained signals from extracellular Pgi1p and Eno2p conjugated with EGFP-FLAG-tag using anti-Pgi1p and anti-FLAG were processed by setting signals obtained from 0.4 ng/lane of FLAG-protein as 1. Relative amounts of Eno2p-EGFP-FLAG-tag were calculated as: [signal intensities of anti-FLAG treatment/ that of anti-Pgi1p treatment]. One-tailed t-tests were performed to detect significant differences.

Fluorescence microscopy

For confocal microscopy, the cells were grown to the mid-log phase and fixed with PBS (pH 7.4) containing 3.7% paraformaldehyde. The cells were then fixed to the bottom of a 35-mm glass-base dish (Synapse Fine View Dish SF-G-D27; FPI Inc., Kyoto, Japan) by using the same buffer. The fluorescence images were obtained at room temperature with a 60× objective (oil immersion NA, 1.35) by using a laser-scanning confocal microscope (FluoView FV1000; Olympus) and FV10-ASW software (Olympus). The efficiency of colocalization was analyzed using ImageJ software (http://rsb.info.nih.gov/ij/). To observe the cells producing recombinant proteins and perform time-course observations, an epifluorescence microscope IX71 (Olympus) with a 100× objective (oil immersion NA, 1.40) and Aquacosmos software (Hamamatsu Photonics, Hamamatsu, Japan) were used.

Time-course observation of the living cells on agarose pad

To observe the time-dependent localization changes of the foci, the agarose pad was prepared using a slightly modified method (Tanaka et al. 2010). Briefly, 2% agarose was added to the SD+HM media, heated, and dissolved. The solution at 60°C was spotted onto the slide glass with vinyl tape wrapped on each side. Immediately following this, the cover glass was overlaid and left at room temperature. Before observation, the yeast culture in the mid-log phase with an OD600 of 0.4 was spotted onto the agarose pad and covered with the cover glass. Time-lapse observations were conducted by fitting a small incubator (MI-IBC-IF; Olympus) onto the microscopy system and by manually photographing at every 5 min for 30 min. The incubator was pre-warmed to 30°C, and the excitation light source was turned on only during image recording.
<table>
<thead>
<tr>
<th>Plasmid</th>
<th>Oligo name</th>
<th>Description</th>
<th>Sequence (5'-3')</th>
</tr>
</thead>
<tbody>
<tr>
<td>pUL1</td>
<td>GAP-Pro-F</td>
<td>Primer for amplification of MCS-tGAPDH</td>
<td>CTAAACCTTCTAATCTACTTTTTATAGTTAGTC</td>
</tr>
<tr>
<td>KpnI-TGAP-R</td>
<td>Primer for amplification of MCS-tGAPDH</td>
<td>ATGCTGTACCTCAATCAATGAGAAATGGTCTATTAAATAG</td>
<td></td>
</tr>
<tr>
<td>pUL-ATG-EGFP</td>
<td>Oligonucleotide for OSCoM (forward)</td>
<td>AATTCATGC</td>
<td></td>
</tr>
<tr>
<td>EcATGxhOSCoM_R</td>
<td>Oligonucleotide for OSCoM (reverse)</td>
<td>TGAGGATCATG</td>
<td></td>
</tr>
<tr>
<td>pRS423-ATG-EGF GAPDH promoter -F</td>
<td>Primer for amplification of pGAPDH-EGFP-FLAGtag-tGAPDH (forward)</td>
<td>GTCACGGGATTTACGAGTCTTCACACAGGAAACACCA</td>
<td></td>
</tr>
<tr>
<td>GAPDH terminator -R</td>
<td>Primer for amplification of pGAPDH-EGFP-FLAGtag-tGAPDH (forward)</td>
<td>ATAAAGATGCGGCGTCAATCAATGAGAAATGGTCTATTAAAATAG</td>
<td></td>
</tr>
<tr>
<td>pUL-ATG-DsRED</td>
<td>DsRed-EcoR1ATGxho1</td>
<td>F Primer for amplification of DsRED from pKRD4 (forward)</td>
<td>TAAACAGAATTCTATGCTGAGGGTGATCTGTTGCGACAAACACGCA</td>
</tr>
<tr>
<td>DsRed-Sal1 R</td>
<td>Primer for amplification of DsRED from pKRD4 (reverse)</td>
<td>GTTCAACACAGTCTGTTCTGAGGGTGATCTGTTGCGACAAACACGCA</td>
<td></td>
</tr>
<tr>
<td>seqDsRED(27-34)</td>
<td>Primer for sequencing DsRED</td>
<td>CGAGTTCAATGCGCTTCAGG</td>
<td></td>
</tr>
<tr>
<td>pULG2</td>
<td>pUL5G1mcskaiF</td>
<td>Oligonucleotide for OSCoM (forward)</td>
<td>AATTCGAGATCCGGTCAAGGCGGAGATTCGCTGAGGT</td>
</tr>
<tr>
<td>pUL5G2mcskaiR</td>
<td>Oligonucleotide for OSCoM (reverse)</td>
<td>TCAGCCGGGTGAGCTCCGGAGATTCGCTGAGGT</td>
<td></td>
</tr>
<tr>
<td>pULG2-ATG-HA</td>
<td>ATG-HA tagF (pULG2)</td>
<td>Oligonucleotide for OSCoM (forward)</td>
<td>GATACGCGGATCGGAACACGCAATGCTATGAGGTACAG</td>
</tr>
<tr>
<td>ATG-HA tagR (pULG2)</td>
<td>Oligonucleotide for OSCoM (reverse)</td>
<td>GATACGCGGATCGGAACACGCAATGCTATGAGGTACAG</td>
<td></td>
</tr>
<tr>
<td>pULG2-ENO2/ pULG2-HA-EN02</td>
<td>pULG-en20 F (BanH1)</td>
<td>Primer for amplification of EN02 (forward)</td>
<td>GAATTCGAGATCCGCTGCTGTCAAAGTTTACCTAC</td>
</tr>
<tr>
<td>pULG-en20all R (Sac1)</td>
<td>Primer for amplification of EN02 (reverse)</td>
<td>CGACCGGGACTGCTCAACTGTGATGGGTAAGT</td>
<td></td>
</tr>
<tr>
<td>eno2-1 F</td>
<td>Primers for cloning ENO2 from genome and for sequencing</td>
<td>ATACAGAACAGTACAGTAAC</td>
<td></td>
</tr>
<tr>
<td>eno2-2 F</td>
<td>TGATTTCTTCTTATGTGAGT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>eno2-3 F</td>
<td>ACTGGAATTACACCCGAA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>eno2-4 F</td>
<td>TCTGTTGTTCTTGTGAGT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>eno2-5 F</td>
<td>GTTCCGAAGTTTACCAAC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>eno2-6 F</td>
<td>TCAAGACGATGAGTACG</td>
<td></td>
<td></td>
</tr>
<tr>
<td>eno2-7 F</td>
<td>ACTGGGAAATCGTGCTCAC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>eno2-8 F</td>
<td>CTGTGGAAGTCAAGAC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>eno2-9 F</td>
<td>TTTACAAAGACTGCTGCTG</td>
<td></td>
<td></td>
</tr>
<tr>
<td>eno2-10 R</td>
<td>AAGCGTATTGCTTGTGAGC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>pULG2-CDC19</td>
<td>CDC19-BamH1 F</td>
<td>Primer for amplification of CDC19 (forward)</td>
<td>AACAGAATTCGGAATCTGCTTCTAGATTGAAGATTGACCTCATTA</td>
</tr>
<tr>
<td>CDC19-Xho1 R</td>
<td>Primer for amplification of CDC19 (reverse)</td>
<td>GAGATCTCGGGATCAACGCTGAGAAGTTATGCAATGAGATTTGAGGAGT</td>
<td></td>
</tr>
<tr>
<td>CDC19 (291-316) seqF</td>
<td>Primers for sequencing CDC19</td>
<td>CSATGTTGGACTACCAACATTC</td>
<td></td>
</tr>
<tr>
<td>CDC19 (681-706) seqF</td>
<td>Primer for amplification of CDC19 (forward)</td>
<td>CTTGGATCTAAGACAGTTAG</td>
<td></td>
</tr>
<tr>
<td>CDC19 (1078-1097) seqF</td>
<td>Primer for amplification of CDC19 (reverse)</td>
<td>GCTTACTGCCAAGACTACAG</td>
<td></td>
</tr>
<tr>
<td>CDC19 (1306-1325) seqF</td>
<td>Primer for amplification of CDC19 (forward)</td>
<td>TACAGAGGGTGTCTTCCATT</td>
<td></td>
</tr>
<tr>
<td>pULG2-PYK2</td>
<td>PYK2-BamH1 F</td>
<td>Primer for amplification of PYK2 (forward)</td>
<td>AACAGAAATTCGGAATCTGCTTCTAGATTGAAGATTGACCTCATTA</td>
</tr>
<tr>
<td>PYK2-Xho1 R</td>
<td>Primer for amplification of PYK2 (reverse)</td>
<td>GAGATCTCGGGATCAACGCTGAGAAGTTATGCAATGAGATTTGAGGAGT</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Genes</th>
<th>Primers</th>
<th>Primer sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>pULG2-PYK2</strong></td>
<td>PYK2 (211-230) seqF</td>
<td>Primers for sequencing PYK2</td>
</tr>
<tr>
<td></td>
<td>PYK2 (592-611) seqF</td>
<td>AAATCGGAAAGACAAATTCCTC</td>
</tr>
<tr>
<td></td>
<td>PYK2 (993-1012) seqF</td>
<td>ATGAAAGAGCTGCCGTAATCTG</td>
</tr>
<tr>
<td></td>
<td>PYK2 (1333-1355) seqF</td>
<td>TATGCTTTCTGGAAGAACG</td>
</tr>
<tr>
<td><strong>pULG2-GPM1</strong></td>
<td>GPM1-BamH1 F</td>
<td>Primer for amplification of GPM1 (forward)</td>
</tr>
<tr>
<td></td>
<td>GPM1-Xho1 R</td>
<td>Primer for amplification of GPM1 (reverse)</td>
</tr>
<tr>
<td></td>
<td>GPM1 (293-290) seqF</td>
<td>AAAGGTTAAGGCAGAGGGGGTG</td>
</tr>
<tr>
<td><strong>pULG2-TP1</strong></td>
<td>TP1-BamH1 F</td>
<td>Primer for amplification of TP1 (forward)</td>
</tr>
<tr>
<td></td>
<td>TP1-Xho1 R</td>
<td>Primer for amplification of TP1 (reverse)</td>
</tr>
<tr>
<td></td>
<td>TP1 (243-262) seqF</td>
<td>GGAAGAAGCTGTTCTCTG</td>
</tr>
<tr>
<td><strong>pULG2-PGI1</strong></td>
<td>PGI1-BamH1 F</td>
<td>Primer for amplification of PGI1 (forward)</td>
</tr>
<tr>
<td></td>
<td>PGI1-Xho1 R</td>
<td>Primer for amplification of PGI1 (reverse)</td>
</tr>
<tr>
<td></td>
<td>PGI1 (252-271) seqF</td>
<td>TAAAGGCTCCGAGATTGAG</td>
</tr>
<tr>
<td></td>
<td>PGI1 (697-716) seqF</td>
<td>GCGGAAGAATCTGTTCTG</td>
</tr>
<tr>
<td></td>
<td>PGI1 (1179-1197) seqF</td>
<td>TATCCCATCAAGCTCCTTC</td>
</tr>
<tr>
<td><strong>pULG2-PGK1</strong></td>
<td>PGK1-BamH1 F</td>
<td>Primer for amplification of PGK1 (forward)</td>
</tr>
<tr>
<td></td>
<td>PGK1-Xho1 R</td>
<td>Primer for amplification of PGK1 (reverse)</td>
</tr>
<tr>
<td></td>
<td>PGK1 (221-240) seqF</td>
<td>TACCTCTTTCATGGTCT</td>
</tr>
<tr>
<td></td>
<td>PGK1 (510-529) seqF</td>
<td>TCGATCTTTGTTCTCTGG</td>
</tr>
<tr>
<td></td>
<td>PGK (848-867) seqF</td>
<td>CTGCCCATCTCAAGAGTC</td>
</tr>
<tr>
<td><strong>pULG2-FBA1</strong></td>
<td>FBA1-BamH1 F</td>
<td>Primer for amplification of FBA1 (forward)</td>
</tr>
<tr>
<td></td>
<td>FBA1-Xho1 R</td>
<td>Primer for amplification of FBA1 (reverse)</td>
</tr>
<tr>
<td></td>
<td>FBA1 (206-315) seqF</td>
<td>CAGCTTACGATCTCCAGT</td>
</tr>
<tr>
<td></td>
<td>FBA1 (652-667) seqF</td>
<td>TTGGCACCACAATCTC</td>
</tr>
<tr>
<td><strong>pUL-eno(1-10)</strong></td>
<td>Eno(1-10) Xho1F</td>
<td>Primers for cloning ENO2 fragments</td>
</tr>
<tr>
<td><strong>pUL-eno(1-28)</strong></td>
<td>Eno(1-28) Xho1F</td>
<td>CAGCAGTCACCATGGAGAGTCAGCTC</td>
</tr>
<tr>
<td><strong>pUL-eno(1-30)</strong></td>
<td>Eno(1-30) Xho1F</td>
<td>AAGCAGACGCATCAGGATCAGTCAGCTC</td>
</tr>
<tr>
<td><strong>pUL-eno(1-50)</strong></td>
<td>Eno(1-50) Xho1F</td>
<td>CAGCAGTCACCATGGAGAGTCAGCTC</td>
</tr>
<tr>
<td><strong>pUL-eno(1-110)</strong></td>
<td>Eno(1-110) Xho1F</td>
<td>CAGCAGTCACCATGGAGAGTCAGCTC</td>
</tr>
<tr>
<td><strong>pUL-eno(1-169)</strong></td>
<td>Eno(1-169) Xho1F</td>
<td>CAGCAGTCACCATGGAGAGTCAGCTC</td>
</tr>
<tr>
<td><strong>GAPDH promoter p3AP_F</strong></td>
<td></td>
<td>Primer for sequencing</td>
</tr>
<tr>
<td><strong>p413-ADH-TLG2</strong></td>
<td>BamH1-TLG2 F</td>
<td>Primer for amplification of TLG2 (forward)</td>
</tr>
<tr>
<td></td>
<td>Xho1-TLG2 R</td>
<td>Primer for amplification of TLG2 (reverse)</td>
</tr>
<tr>
<td></td>
<td>ADH pro F</td>
<td>Primer for sequencing p413-ADH plasmid</td>
</tr>
<tr>
<td></td>
<td>TLG2 (140-164) seqF</td>
<td>ATGAGCAAGGATGATACG</td>
</tr>
<tr>
<td></td>
<td>TLG2 (444-466) seqF</td>
<td>AGAAGTGGAGATGATGAGC</td>
</tr>
<tr>
<td></td>
<td>TLG2 (786-807) seqF</td>
<td>AGAAGTGGAGATGATGAGC</td>
</tr>
<tr>
<td>ΔTLG2 (genome) TLG2 (col0P) F</td>
<td>Primers for checking the sizes of coding regions</td>
<td>GCAAGACAGGAAAGTCTCCAA</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>-----------------------------------------------</td>
<td>------------------------</td>
</tr>
<tr>
<td>ΔTLG2 (col0P) R</td>
<td></td>
<td>GCAACAGGTATATGAAACGCT</td>
</tr>
<tr>
<td>KanMX4 (gene) KanB-R</td>
<td>Primmers for checking genotypes</td>
<td>CTGCAGCGAGGACGCGTAAT</td>
</tr>
<tr>
<td>ΔSEC22 (genome SEC22 (col0P) F</td>
<td></td>
<td>AATTTTCAACCAACGCTTTGTACT</td>
</tr>
<tr>
<td>ΔGOS1 (genome) GOS1 (col0P) F</td>
<td></td>
<td>AAAGATGCTTATGAAAAATCTCACG</td>
</tr>
<tr>
<td>ΔPEP12 (genome PEP12 (col0P) F</td>
<td></td>
<td>TGCCCTAGCTGGAAAAATTGATTTA</td>
</tr>
<tr>
<td>ΔVPSS1 (genome VPSS1 (col0P) F</td>
<td></td>
<td>AATCTACCCAGGCTTTAAAGATG</td>
</tr>
<tr>
<td>ΔBTN2 (genome) BTN2 (col0P) F</td>
<td></td>
<td>CGAGAGTTGGATCCAGTTTCTTG</td>
</tr>
<tr>
<td>ΔSNC2 (genome) SNC2 (col0P) F</td>
<td></td>
<td>AGTGATCTTGCTACATGATATACG</td>
</tr>
<tr>
<td>ΔSNX4 (genome) SNX4 (col0P) F</td>
<td></td>
<td>AATAACAGGAAAATCTATGCC</td>
</tr>
<tr>
<td>ΔSOS1 (genome) SOS1 (col0P) F</td>
<td></td>
<td>CACACTAAGGACAAAAAGGTATAG</td>
</tr>
<tr>
<td>ΔSOS2 (genome) SOS2 (col0P) F</td>
<td></td>
<td>TACCAATAAGAGGCTGAAAGT</td>
</tr>
<tr>
<td>ΔATG1 (genome) ATG1 (col0P) F</td>
<td></td>
<td>AATTTAAGTTAGCAGCCATCTTTT</td>
</tr>
<tr>
<td>ΔATG20 (genome ATG20 (col0P) F</td>
<td></td>
<td>ATAAAGCTTGCTTTTCTTCTACT</td>
</tr>
<tr>
<td>ΔATG17 (genome ATG17 (col0P) F</td>
<td></td>
<td>CTTGAATTATATCTTCTCAGCC</td>
</tr>
<tr>
<td>Category</td>
<td>Accession</td>
<td>Name</td>
</tr>
<tr>
<td>---------------------------</td>
<td>-----------</td>
<td>------</td>
</tr>
<tr>
<td><strong>Organelle marker proteins</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>YGL008C</td>
<td>PMA1</td>
<td></td>
</tr>
<tr>
<td>TDL116W</td>
<td>NUP84</td>
<td></td>
</tr>
<tr>
<td>YKL029C</td>
<td>MAE1</td>
<td></td>
</tr>
<tr>
<td>YLR330W</td>
<td>CHS5</td>
<td></td>
</tr>
<tr>
<td>YLR025W</td>
<td>SNF7</td>
<td></td>
</tr>
<tr>
<td>YGL225W</td>
<td>VRG4</td>
<td></td>
</tr>
<tr>
<td>YOL147C</td>
<td>PEX11</td>
<td></td>
</tr>
<tr>
<td>YLR208W</td>
<td>SEC13</td>
<td></td>
</tr>
<tr>
<td><strong>SNAREs</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>YPL232W</td>
<td>SSO1</td>
<td></td>
</tr>
<tr>
<td>YMR183C</td>
<td>SSO2</td>
<td></td>
</tr>
<tr>
<td>YLR268W</td>
<td>SEC22</td>
<td></td>
</tr>
<tr>
<td>YOR327C</td>
<td>SNC2</td>
<td></td>
</tr>
<tr>
<td>YOL018C</td>
<td>TLG2</td>
<td></td>
</tr>
<tr>
<td>YGR142W</td>
<td>BTN2</td>
<td></td>
</tr>
<tr>
<td>YOR036W</td>
<td>PEP12</td>
<td></td>
</tr>
<tr>
<td>YKR020W</td>
<td>VPS51</td>
<td></td>
</tr>
<tr>
<td>YHL031C</td>
<td>GOS1</td>
<td></td>
</tr>
<tr>
<td>YOR106W</td>
<td>VAM3</td>
<td></td>
</tr>
<tr>
<td><strong>Transport</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>YDR517W</td>
<td>GRH1</td>
<td></td>
</tr>
<tr>
<td><strong>Autophagy-related proteins</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>YGL180W</td>
<td>ATG1</td>
<td></td>
</tr>
<tr>
<td>YBL078C</td>
<td>ATG8</td>
<td></td>
</tr>
<tr>
<td>YPR049C</td>
<td>ATG11</td>
<td></td>
</tr>
<tr>
<td>YLR423C</td>
<td>ATG17</td>
<td></td>
</tr>
<tr>
<td>YDL113C</td>
<td>ATG20</td>
<td></td>
</tr>
<tr>
<td><strong>Cell wall protein</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>YDR077W</td>
<td>SED1</td>
<td></td>
</tr>
<tr>
<td>Cellular process</td>
<td>Accession</td>
<td>SGDID</td>
</tr>
<tr>
<td>---------------------------</td>
<td>------------</td>
<td>----------</td>
</tr>
<tr>
<td><strong>Metabolism</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glycolysis</td>
<td>YHR174W</td>
<td>S000001217</td>
</tr>
<tr>
<td></td>
<td>YGR192C</td>
<td>S000003424</td>
</tr>
<tr>
<td></td>
<td>YCR012W</td>
<td>S000000605</td>
</tr>
<tr>
<td></td>
<td>YJL052W</td>
<td>S000003588</td>
</tr>
<tr>
<td></td>
<td>YDR050C</td>
<td>S000002457</td>
</tr>
<tr>
<td></td>
<td>YJR009C</td>
<td>S000003769</td>
</tr>
<tr>
<td></td>
<td>YGR254W</td>
<td>S000003486</td>
</tr>
<tr>
<td></td>
<td>YKL152C</td>
<td>S000001635</td>
</tr>
<tr>
<td></td>
<td>YAL038W</td>
<td>S000000336</td>
</tr>
<tr>
<td></td>
<td>YBR166C</td>
<td>S000000400</td>
</tr>
<tr>
<td></td>
<td>YKL060C</td>
<td>S000001543</td>
</tr>
<tr>
<td>Amino acid biosynthesis</td>
<td>YER091C</td>
<td>S000000893</td>
</tr>
<tr>
<td>Methionine biosynthesis</td>
<td>YIL051C</td>
<td>S000001313</td>
</tr>
<tr>
<td>Isoeucine biosynthesis</td>
<td>YDR158W</td>
<td>S000002565</td>
</tr>
<tr>
<td>Methionine and threonine</td>
<td>YAL044C</td>
<td>S000000042</td>
</tr>
<tr>
<td>Glycine catabolic process</td>
<td>YIL094C</td>
<td>S000001356</td>
</tr>
<tr>
<td>Lysine biosynthesis</td>
<td>YCR020W</td>
<td>S000005728</td>
</tr>
<tr>
<td>Histidine biosynthesis</td>
<td>YKL085W</td>
<td>S000001568</td>
</tr>
<tr>
<td>TCA cycle</td>
<td>YPR074C</td>
<td>S000006278</td>
</tr>
<tr>
<td>Pentose phosphate pathway</td>
<td>YLR044C</td>
<td>S000004034</td>
</tr>
<tr>
<td>Alcoholic fermentation</td>
<td>YGR037C</td>
<td>S000003269</td>
</tr>
</tbody>
</table>
## Table 3. List of identified noncovalently-bound cell surface proteins (continued)

| Protein binding | YAL005C | S000000044 SSA1 | protein folding and nuclear localization signal (NLS)-directed nuclear transport | 642 | 69.6 | 5.1 | 5 | 5 | 3 |
| Homeostasis | YMR186W | S0000007988 HSC82 | Cytoplasmic chaperone of the Hsp90 family | 705 | 80.8 | 4.8 | 4 | 8 | 2 |
| | YDR155C | S000002562 CPR1 | Cytoplasmic peptidyl-prolyl cis-trans | 162 | 17.4 | 7.4 | 17 | 6 | 2 |
| | YLL050C | S000003973 COF1 | Coflin (Actin binding) | 143 | 15.9 | 5.2 | 22 | 4 | 2 |
| | YBR109C | S000000313 CMD1 | Calmodulin | 147 | 16.1 | 4.3 | 21 | 3 | 2 |
| | YJR034W | S000003571 KAR2 | ATPase involved in protein import into the Thioredoxin peroxidase | 682 | 74.4 | 4.9 | 3 | 2 | 2 |
| | YML028W | S000004490 TSA1 | Cytoplasmic thioredoxin isoenzyme | 103 | 11.2 | 4.9 | 49 | 8 | 4 |
| | YLR043C | S000004033 TRX | Cytoplasmic thioredoxin isoenzyme | 104 | 11.2 | 4.9 | 49 | 8 | 4 |
| | YGR209C | S000003441 TRX2 | Heat Shock Protein | 109 | 11.7 | 5.4 | 23 | 4 | 3 |
| | YFL014W | S000001880 HSP12 | Mitochondrial manganese superoxide | 233 | 25.8 | 8.5 | 17 | 2 | 2 |
| | YHR008C | S000001050 SOD2 | Translation initiation factor eIF4A | 395 | 44.7 | 5.1 | 10 | 8 | 3 |
| | YDL034W | S000000760 HYP2 | Translation elongation factor eIF-5A | 157 | 17.1 | 5 | 19 | 12 | 2 |
| | YDR385W | S000002793 EFT2 | Elongation factor 2 | 842 | 93.2 | 6.3 | 3 | 2 | 2 |
| | YDR382W | S000002790 RPP2B | Ribosomal protein P2 | 110 | 11.1 | 4.1 | 24 | 2 | 2 |
| Folding | YCL043C | S000000548 PDI1 | Protein disulfide isomerase | 522 | 58.2 | 4.5 | 27 | 28 | 10 |
| Signaling | YMR116C | S000004722 ASC1 | and guanine nucleotide dissociation inhibitor for Gap23 and BAR domain-containing protein | 319 | 34.8 | 6.2 | 34 | 28 | 8 |
| Traffic | YDL041W | S000001303 GVP36 | Zinc- and pH-regulated surface protein | 326 | 36.6 | 5 | 20 | 6 | 4 |
| Unknown | YOL154W | S000005514 ZPS1 | Membrane-bound peptidyl-prolyl cis-trans isomerase (PPlase) | 249 | 27.5 | 5 | 27 | 17 | 5 |
| | YDR519W | S000002927 FPR2 | Membrane-bound peptidyl-prolyl cis-trans isomerase (PPlase) | 135 | 14.5 | 5.5 | 34 | 8 | 3 |
| | YPL25W | S0000081 YPL225 | Unknown | 146 | 17.4 | 5.3 | 16 | 4 | 2 |
Results

Detection of unconventional secretion of glycolytic enzymes

2D-HPLC-based cell surface proteome analysis was done to detect the extracellular presence of 11 glycolytic enzymes, namely, enolases (Eno1p and Eno2p), glyceraldehyde-3-phosphate dehydrogenases (Tdhlp, Tdh2p, and Tdh3p), 3-phosphoglycerate kinase (Pgk1p), fructose 1,6-bisphosphate aldolase (Fba1p), phosphoglucone isomerase (Pgi1p), triose phosphate isomerase (Tpi1p), phosphoglycerate mutase (Gpm1p), and pyruvate kinase (Cdc19p; Table 3 and 4). To shortlist the candidate proteins for analysis of the secretory pathway, the detected glycolytic enzymes were produced as recombinant proteins fused to EGFP-FLAG. Although all the glycolytic enzymes were successfully produced in the cell, only 4 (Eno2p, Pgi1p, Tpi1p, and Fba1p) were reproducibly detected in the culture media (Fig. 2A left). Among these, Eno2p and Pgi1p were both thought to be important molecules when secreted, and thus, were used for further investigation. To examine whether Eno2p and Pgi1p were secreted via the conventional pathway, a sec23-1 temperature-sensitive mutant strain was used. The secretion of EGFP fused with the conventional glucoamylase secretion signal sequence was successfully inhibited at 37°C. Comparatively, under the same conditions, by using the same strain, both Eno2p and Pgi1p were detected in the culture media (Fig. 2B). To examine whether a cleavable peptide sequence existed at the N-terminus of Eno2p, which is typical for conventionally secreted proteins, an extra N-terminal peptide sequence (in this case, HA-tag) was added to Eno2p. In the wild-type cells, Eno2p with the extra N-terminal peptide sequence was detected in the culture media as well as Eno2p without the extra sequence (Fig. 2C). These results suggest that glycolytic enzymes, at least Eno2p, can be secreted via an unconventional pathway in *S. cerevisiae*. Among the glycolytic enzymes detected in the culture media, Pgi1p-EGFP-FLAG gave the clearest bands. Moreover, the secretion of endogenous Pgi1p has been detected in the previous study (Oliveira et al. 2010). Therefore, I used endogenous Pgi1p as a control in the following experiments.

Table 4 List of identified noncovalently-bound cell surface proteins

<table>
<thead>
<tr>
<th>Cellular process</th>
<th>Number of identified proteins</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Metabolism</strong></td>
<td></td>
</tr>
<tr>
<td>Glycolysis</td>
<td>11</td>
</tr>
<tr>
<td>Amino acid biosynthesis</td>
<td>6</td>
</tr>
<tr>
<td>TCA cycle</td>
<td>1</td>
</tr>
<tr>
<td>Pentose phosphate pathway</td>
<td>1</td>
</tr>
<tr>
<td>Alcoholic fermentation</td>
<td>1</td>
</tr>
<tr>
<td>Fatty acid metabolism</td>
<td>1</td>
</tr>
<tr>
<td><strong>Protein binding</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>6</td>
</tr>
<tr>
<td><strong>Homeostasis</strong></td>
<td>5</td>
</tr>
<tr>
<td><strong>Translation</strong></td>
<td>4</td>
</tr>
<tr>
<td><strong>Signaling</strong></td>
<td>1</td>
</tr>
<tr>
<td><strong>Folding</strong></td>
<td>1</td>
</tr>
<tr>
<td><strong>Traffic</strong></td>
<td>1</td>
</tr>
<tr>
<td><strong>Unknown</strong></td>
<td>3</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>42</td>
</tr>
</tbody>
</table>
Searching for the enolase sequence responsible for secretion

N-terminal fragments of Eno2p containing 169 amino acids (1–169) were prepared in reference with the previous report (29). In addition, N-terminal fragments of Eno2p containing 17, 28, 30, 50, and 110 amino acids (1–17), (1–28), (1–30), (1–50), and (1–110)) were prepared. Subsequently, the (1–28), (1–50), and (1–169) fragments were reproducibly detected in the culture media (Fig.3A). In addition, secretion of the (1–28) Eno2p fragment (eno(1–28)) conjugated to EGFP and FLAG in the sec23-1 strain was not inhibited at 37°C (Fig. 3B). These results suggest that eno(1–28), as well as Eno2p, is secreted via an unconventional pathway.

Fig. 2 Detection of unconventional secretion of glycolytic enzymes Anti-FLAG antibody was used for detection. A: Secretion of glycolytic enzymes. (Left) secreted proteins. (Right) cellular proteins. I1, pUL11; SG1C, pULSG1C; ATG, pUL-ATG-EGFP; PYK2, pULGI2-PYK2; CDC19, pULGI2-CDC19; ENO2, pULGI2-ENO2; GPM1, pULGI2-GPM1; PGK1, pULGI2-PGK1; TPI1, pULGI2-TPI1; FBA1, pULGI2-FBA1; PGI1, pULGI2-PGI1. B: The effect of inhibition of the conventional pathway on the secretion of the glycolytic enzymes. Secretion of recombinant proteins in sec23-1 strains under 25°C or 37°C is shown. C: The effect of the N-terminal peptide (HA-tag) on the secretion of enolase. Control (secretion signal +, secretion of EGFP-FLAG protein with conventional secretion signal sequence), pULSG1C; control (secretion signal -, secretion of EGFP-FLAG protein without secretion signal sequence), pUL-ATG-EGFP; ENO2 (peptide addition +, secretion of N-terminal HA peptide-tagged Eno2p-EGFP-FLAG), pULGI2-ATG-HA-ENO2; ENO2 (peptide addition -, secretion of Eno2p-EGFP-FLAG without peptide addition),
pULGI2-ENO2. Similar results were obtained from 3 independent experiments. *Glycolytic enzymes conjugated to EGFP and FLAG. Additional bands are either nonspecific binding of antibody or degradation products of target proteins.

Fig. 3 Detection and monitoring of the secretion of the N-terminal fragment of enolase conjugated to EGFP and FLAG  
B: SEC23-independent secretion of the enolase fragment. Secretion of recombinant proteins in sec23-1 strains under 25°C or 37°C is shown. (1–28), pUL-eno(1–28); ALL, pULGI2-ENO2; 37, cultivated at 37°C; 25: cultivated at 25°C. C: Fluorescence microscopy of cells transformed with pUL-eno(1–28), pULGI2-ENO2, and pULGI2-PGI1. Scale bar: 10 μm. Similar results were obtained from 3 independent experiments.
Fig. 4 Time-dependent localization change of the eno(1–28) fragment fused to EGFP. Scale bar: 5 μm.

Fig. 5 Colocalization of the enolase fragment conjugated to DsRED and the GFP-tagged organelle markers. The fixed cells were observed at room temperature. The numbers of cells forming foci are shown in Table 5. White arrow, foci colocalized with organelle markers. Scale bar: 5 μm.
Fig. 6 Co-localization of the enolase fragment conjugated to DsRED and the organelle markers conjugated to GFP (continued from Fig. 5).

Control 1, wild-type cells transformed with pUL-eno(1–28); control 2, wild-type cells transformed with pUL-ATG-EGFP. Scale bar: 5 μm.
Table 5 Calculation of Figure 5 and 6

<table>
<thead>
<tr>
<th>Organelle marker</th>
<th>a. Number of cells forming DsRED foci</th>
<th>b. Number of cells with GFP fluorescence</th>
<th>c. Number of cells with colocalized foci</th>
<th>c/a [%]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nup84p</td>
<td>28</td>
<td>72</td>
<td>19</td>
<td>68</td>
</tr>
<tr>
<td>Pma1p</td>
<td>21</td>
<td>224</td>
<td>14</td>
<td>67</td>
</tr>
<tr>
<td>Snf7p</td>
<td>28</td>
<td>77</td>
<td>15</td>
<td>54</td>
</tr>
<tr>
<td>Chs5p</td>
<td>20</td>
<td>80</td>
<td>9</td>
<td>45</td>
</tr>
<tr>
<td>Sec13p</td>
<td>20</td>
<td>159</td>
<td>8</td>
<td>40</td>
</tr>
<tr>
<td>Pex11p</td>
<td>48</td>
<td>40</td>
<td>16</td>
<td>33</td>
</tr>
<tr>
<td>Vrg4p</td>
<td>41</td>
<td>198</td>
<td>15</td>
<td>27</td>
</tr>
<tr>
<td>Mae1p</td>
<td>72</td>
<td>27</td>
<td>1</td>
<td>3.7</td>
</tr>
</tbody>
</table>

**Foci formation and intracellular translocation of eno(1–28)**

To monitor the secretion of the eno(1–28) fragment, the cells producing eno(1–28) conjugated with EGFP and FLAG were observed by fluorescence microscopy (Fig. 3C). The green fluorescence from EGFP was detected as a dot, suggesting that eno(1–28) formed foci. In addition, some of the foci changed location when observed at 30°C on the agarose pad (Fig. 4).

**Colocalization of eno(1–28) with organelle marker proteins**

To examine the localization of the foci formed by eno(1–28) in the cells, eno(1–28) conjugated with the DsRED monomer was produced in the GFP clones carrying the organelle-marker protein-coding genes (Table 2; PMA1 (plasma membrane), NUP84 (nuclear membrane), MAE1 (mitochondria), CHS5 (exomer), SNF7 (endosome and multivesicular body (MVB) vesicle), VRG4 (cis-Golgi), PEX11 (peroxisome), and SEC13 (ER to Golgi transport vesicle)), fused with the GFP-coding sequence at the 3′-end. Our results showed that eno(1–28)-DsRED colocalized with the plasma membrane, nuclear membrane, exomer, endosome/MVB vesicle, Golgi, and peroxisome, but not with the mitochondria (Fig. 5, 6, and Table 5).
Fig. 7 Intracellular SNARE dependence of Eno2p and Pgi1p secretion

A: Secretion in strains transformed with Eno2-expressing plasmids. Cont., wild-type BY4741 cells transformed with pUL-ATG-EGFP; wt, wild-type BY4741 cells transformed with pULGI2-ENO2; Δ, knockout strains transformed with pULGI2-ENO2.

B: Calculated amounts of secreted Eno2p by comparison to the levels of Pgi1p secreted. Values are the mean ± SEM of ≥3 independent experiments.
Inhibition of enolase secretion by knockout strains

Knockout strains of SNAREs (see Table 2; SEC22, GOS1, PEP12, TLG2, VPS51, BTN2, SNC2, SNX4, SSO1, and SSO2), which play a major role in intracellular protein transportation were utilized to examine their effects on the secretion of Eno2p conjugated with EGFP and endogenous Pgi1p (Fig. 7A). Pgi1p was detected in the culture media of all strains, while the levels of Eno2p-EGFP-FLAG were lower in the culture media of the TLG2 knockout strain. Inhibition of the translocation of Eno2p-EGFP-FLAG to the cell surface was also tested using immunostaining (Fig. 7B). The ATG1, ATG8, ATG11, ATG17, ATG20, VAM3, and GRH1 knockout strains (see Table 2) as well as wild-type BY4741 were further tested to investigate the role of autophagy-related genes in secretion (Fig. 9). The secretion of Eno2p was not inhibited in the knockout strains of the autophagy-related genes, demonstrating that of all the SNARE and autophagy-related genes analyzed, only the TLG2 knockout strain inhibited the secretion of Eno2p (Fig. 7A). TLG2-dependency of Eno2p-EGFP-FLAG secretion was further confirmed by complementation of the mutation with a wild-type plasmid (Fig. 8). Therefore, I concluded that Eno2p is secreted by an unknown TLG2-dependent pathway.

Fig. 8 TLG2-dependency of Eno2p secretion A: Secretion in strains transformed with Eno2-expressing plasmids. B: Calculated amounts of secreted proteins by comparison to the levels of Pgi1p secreted. ATG, cells transformed with pUL-ATG-EGFP; ENO2, cells transformed with pULGI2-ENO2; SG1C, cells transformed with pULSG1C, ΔTLG2, TLG2 knockout strains; wt, wild type BY4741 strains; M, marker; Tlg2p -, cells transformed with p413-ADH (control vector); Tlg2p +, cells transformed with p413-ADH-TLG2 (plasmid for producing Tlgp2). Values are the mean ± SEM of ≥3 independent experiments.

48
Fig. 9 Autophagy independency of Eno2p and Pgi1p secretion

A: Western blots. B: Calculated amounts of secreted Eno2p by comparison to the Pgi1p secreted. Values are the mean ± SEM of 3 independent experiments.
Discussion

The 11 glycolytic enzymes detected by the cell surface proteome analysis, including the 4 detected in the secretion analysis, were all previously reported to be secreted or present in the cell wall in *S. cerevisiae* (Nombela et al. 2006, Oliveira et al. 2010). These results demonstrate both the different detection capacities of proteome analysis and western blotting, and the efficacy of our detection method (Table 3). The lower number of glycolytic enzymes detected in the secretion analysis compared to those detected by proteome analysis suggests that the secretion of some of the proteins was undetectable, because the tendency to secrete was too low. However, it is also possible that the conjugated extra amino acid sequence inhibited the secretion of the glycolytic enzymes. I utilized Eno2p to analyze the secretory pathway because enolase secretion is thought to be important for many diseases, and the secretory pathway has not yet been investigated. I utilized Pgi1p as a control because it was detected in high amounts in the culture media. Conjugation of an extra peptide sequence to the N-terminus of Eno2p slightly increased its molecular weight (Fig. 2C), suggesting that Eno2p does not possess a conventional secretion signal sequence that is cleaved during secretion. In addition, Eno2p and Pgi1p were secreted in the sec23-1 mutant at 37°C. These results provide persuasive evidence that the secretion of glycolytic enzymes, at least Eno2p and Pgi1p, is not dependent on the conventional secretory pathway.

Although full-length Eno2p conjugated with EGFP had a broad subcellular localization, the Eno2p fragment formed foci in the cell, and some of the foci changed location from the center of the cell to the cell periphery (Fig. 3C and 4). Therefore, I assumed that the short amino acid sequence of enolase that can be secreted from the cell exemplifies the secretory pathway of enolase. In the previous report, Lopez-Villar and colleagues demonstrated that eno(1–46) and (1–101) did not exist in the cell wall, whereas the eno(1-169) fragment conjugated with glucoamylase did (Lopez-Villar et al. 2006). Recently, Yang et al. identified the hydrophobic domain required for enolase secretion (Yang et al. 2011). The domain includes the 96–132-aa-long region of *S. cerevisiae* enolase that is a conserved membrane-embedded (EM) domain (Yang et al.), and the domain is not identical to 1-28-aa-long region of enolase. Although EM domain is a bacterial domain, eukaryotic *S. cerevisiae* may have similar mechanisms for secretion of enolase. Because the eno(1–28) region has similarity with the 96–132-aa-long region and EM domain of yeast enolase to some extent, respectively, the secretion of eno(1–28) may depend on the same secretion mechanism as that of the 96–132-aa-long region. There may be a sequence in the N-terminal (29–96) region that inhibits secretion, because in contrast to eno(1–28), eno(1–30) was hardly detected in the culture media. It will be important to complete further investigations and to determine the precise signal sequence required for enolase secretion.

Eno(1–28) conjugated with EGFP and FLAG formed foci in the cell, and changed location over time (Fig. 4). The fragment localized to various cellular membranes, but not to the mitochondria (Fig.
It has been previously reported that glycolytic enzymes, including enolase, associate with the post-Golgi vesicles (Forsmark et al. 2011), and that yeast enolase takes part in a macromolecular complex associated with the mitochondria (Brandina et al. 2006), and assists in the transport of tRNA (Entelis et al. 2006). However, the localization of enolase to the mitochondria seems to be regulated by a different region of enolase.

It is reasonable that not all DsRED were colocalized with a particular marker, regarding that enolase colocalized with several markers (Fig. 5, 6, and Table 5). The difference in the number of DsRED and GFP cells reflects the difference in the producing way of each fluorescent protein in the cell; the GFP encoding gene is integrated in the genome of yeast cells, after the each ORF which codes organelle marker protein, whilst DsRED is produced by plasmids. The numbers of GFP-conjugated organelle marker proteins in the cell are dependent on endogenous promoter for each organelle marker protein. Although GFP should be produced in all the cells, some organelle marker proteins are weekly translated and therefore in some case the fluorescence is undetectable. The number of eno(1-28)-DsRED molecules seem to be dependent on transfection efficiency of plasmids, regarding that the plasmid uses the strong GAPDH promoter.

I assumed that the major elements that participate in intracellular trafficking also play a role in the secretion of Eno2p. SNAREs govern the translocation of proteins, and although many SNARE-coding genes are lethal when deleted, some non-lethal deletion mutants are available. I used the SNAREs from the S. cerevisiae genome database (SGD; http://www.yeastgenome.org/) that participate in the translocation of proteins between the Golgi, endosome, and plasma membrane (Table 2). Analyses of the deletion mutants revealed that knocking out TLG2 inhibits enolase secretion. However, I propose other proteins may be involved because the inhibition was not complete. In contrast to the previously reported unconventional secretion of the Acb1 protein (Duran et al. 2010, Manjithaya et al. 2010), secretions of Eno2p and Pgi1p were not inhibited in the GRHI, SSO1, and BTN2 knockout strains (Fig. 7). Therefore, it is probable that regulation of the secretion of these glycolytic enzymes differs from that of the Acb1 protein. There was also no incorporation of the GRASP protein Vps51p; this is surprising as GRASP proteins have been reported to participate in several unconventional secretory pathways (Kinseth et al. 2007, Manjithaya et al. 2010, Giuliani et al. 2011, Schotman et al. 2008). Therefore, the secretion of glycolytic enzymes in S. cerevisiae seems to be independent of the GRASP-regulated pathway. Moreover, Gos1p, which has a role in the cytoplasm-to-vacuole (Cvt) pathway (Bensen et al. 2001), had no influence on the secretion of Eno2p. In addition to its involvement in the Cvt pathway, Tlg2p is a syntaxin-like t-SNARE that participates in vesicle fusion, endocytosis, Golgi-to-vacuole transport, endosomal protein sorting, and protein release from the endoplasmic reticulum (Abeliovich et al. 1999, Coe et a. 1999, Holthuis et al. 1998, Paumet et al. 2001, Gurunathan et al 2002, Mousley et al. 2008). Mousley and colleagues have previously shown that Tlg2p has a role in protein secretion in combination with Sec14p.
(Mousley et al. 2008), and our results suggest that the participation of Tlg2p in the secretion of Eno2p is plausible. Therefore, I conclude that the secretory pathway of glycolytic enzymes is regulated in a different manner compared with the Cvt pathway. *S. cerevisiae* is reported to have autophagosome-mediated membrane compartments for the unconventional secretion of proteins (Bruns et al. 2011), and it is, therefore, possible that the secretion of Eno2p is related to an autophagy-related pathway. However, our results using the knockout strains of autophagy-related proteins (Fig. 9) suggest that the absence of active participation of autophagy-related genes in Eno2p secretion.

Foci formation of N-terminal region of Eno2p conjugated with EGFP has not been reported before. Because plasmids for overexpression were used in this study, the observed foci can be aggregates of proteins. However, for the following three reasons, the foci can be a signature of unknown property of the amino acid sequence of Eno2p. First, although full length of Eno2p was overexpressed in the cell in the same way as N-terminal region, full length Eno2p conjugated with EGFP didn’t form foci. If the N-terminal foci formation was aggregation of proteins, there should be inhibitory sequences of aggregation inside the sequence of Eno2p. Second, the foci were moving in the cell, and colocalized with various membranes of intracellular organelles. Foci forming region was secreted from the cell without degradation. These observations make it plausible that N-terminal region may be the “carrier” region of Eno2p. Since regulation of intracellular and intercellular localization of moonlighting proteins, including enolase, is highly important for their function, N-terminal region of Eno2p can have unknown roles for moonlighting function of Eno2p.

**Summary**

Glycolytic enzymes are cytosolic proteins, while they play important extracellular roles in cell-cell communication and infection. I used *S. cerevisiae* to analyze the secretory pathway of some of these enzymes, including enolase, phosphoglucose isomerase, triose phosphate isomerase, and fructose 1,6-bisphosphate aldolase. Enolase, phosphoglucose isomerase, and an N-terminal 28-aa-long fragment of enolase were secreted in a sec23-independent manner. The EGFP-conjugated enolase fragment formed cellular foci, some of which were found at the cell periphery. Therefore, we speculated that an overview of the secretory pathway can be gained by investigating the colocalization of the enolase fragment with intracellular proteins. The DsRED-conjugated enolase fragment colocalized with membrane proteins at the *cis*-Golgi, nucleus, endosome, and plasma membrane, but not the mitochondria. In addition, the secretion of full-length enolase was inhibited in a knockout mutant of the intracellular SNARE protein-coding gene *TLG2*. The results suggest that enolase is secreted via a SNARE-dependent secretory pathway in *S. cerevisiae*.
References


8. Chertova E, Chertov O, Coren LV, Roser JD, Trubey CM, Bess JW, Sowder RC, Barsov E,
Hood BL, Fisher RJ, Nagashima K, Conrads TP, Veenstra TD, Lifson JD, Ott DE (2006) 
Proteomic and biochemical analysis of purified human immunodeficiency virus type 1 produced 
EZ (2008) Characterization of human mesenchymal stem cell secretome at early steps of 
10. Coe JG, Lim AC, Xu J, Hong W (1999) A role for Tlg1p in the transport of proteins within the 
Autocrine motility factor/glucose-6-phosphate isomerase is a possible predictor of metastasis in 
glycolytic enzyme, enolase, is recruited as a cofactor of tRNA targeting toward mitochondria in 
proteomics of yeast post-Golgi vesicles reveals a discriminating role for Sro7p in protein 
secretion. Traffic. 6: 740-753.
Opin. Cell Biol. 4: 498-504.
protein traffic from the Golgi complex to the cell surface. FASEB J. 13: S251-256.
TGN/endosomal system of yeast. EMBO J. 1: 113-126.
(1988) A short polypeptide marker sequence useful for recombinant protein identification and 
22. Huang D, Shusta EV (2005) Secretion and surface display of green fluorescent protein using the
yeast *Saccharomyces cerevisiae*. Biotechnol. Prog. 2: 349-357.


Biotechnol. 4: 454-462.
CHAPTER II

Foci-formation of enolase under hypoxia

Introduction

Spatial rearrangements of proteins and organelles are often a sign of unexpected phenomena in the cell. Some researchers have found novel phenomena by tracking the fluorescence of protein-conjugated GFP (Huh et al. 2003). For example, in several organisms, purine and CTP synthesis is promoted by the formation of protein complexes (An et al. 2008, Noree et al. 2010, An et al. 2010, Ingerson-Mahar et al. 2010). I have found that recombinant EGFP conjugated with N-terminal (1–28) amino acid residues of enolase (Eno2p) can form fluorescent foci in the cell. In addition to its function as a glycolytic enzyme, Eno2p is known as one of the moonlighting proteins (Jeffery 1999). Moonlighting proteins, which have more than one function, often localize to different sites of the cell in association with particular proteins and cellular components to perform their functions (Jeffery 1999). I speculated that the N-terminal (1–28) amino acid sequence might be the region regulating the intercellular localization of Eno2p. Full-length Eno2p conjugated with EGFP localizes uniformly in the cell in shake culture. If the N-terminal region of Eno2p participates in Eno2p localization, full-length Eno2p conjugated with fluorescent proteins would be expected to form foci under unknown environmental stimuli or in a specific phase of cell life. Moreover, amino acid substitution that inhibits foci formation by the N-terminal region should inhibit foci formation by full-length Eno2p. Comparison of foci-forming and -non-forming cells in conjunction with the inhibition of foci formation by reagents that inhibit specific cellular processes may reveal the mechanisms of the regulation and the biological functions of foci formation.

Ununiformed intracellular localization of glycolytic enzymes has been reported in some organisms and cells. An intracellular assembly of glycolytic enzymes was recently reported in mammalian cells; one of the glycolytic enzymes, GAPDH, conjugated with GFP was found to form fluorescent foci under hypoxia (Agbor et al. 2011). Regulation of metabolic pathways by spatial rearrangement of glycolytic enzymes is plausible, given that changes in carbon metabolism under hypoxia have been reported (Feala et al. 2009, Frezza et al. 2011, Postmus et al. 2012). If foci formation by Eno2p could be triggered by hypoxia, the regulatory pathways and biological effects of foci formation might be the same with hypoxic responses. If this hypothesis were borne out, it would be the first case in which spatial rearrangement of glycolytic enzymes under hypoxia was found to regulate a carbon metabolic pathway.
Materials and methods

Strains and media

The *Escherichia coli* DH5α (F-, Φ80lacZΔM15, Δ(lacZYA-argF)U169, deoR, recA1, endA1, hsdR17(rK-, mK+), phoA, supE44, λ-, thi-1, gyrA96, relA1) strain was used as host cells in the cloning experiments. The yeast strain BY4741 (MATa, his3Δ1, leu2Δ, met15Δ, ura3Δ) and the derived deletion strains of *HOG1* (hog1Δ), *SCH9* (sch9Δ), *SNF1* (snf1Δ), and *UPC2* (upc2Δ) were purchased from EUROSCARF (Frankfurt, Germany). The yeast GFP clones (Invitrogen, Carlsbad, CA, USA) with GFP-tagged endogenous proteins (Eno2p, Eno1p, Hxk1p, Pgi1p, Pfk1p, Fba1p, Tpi1p, Gpd1p, Gpp1p, Znf1p, Sol1p, Gnd1p, Tal1p, Tkl1p, Tdh3p, Pgg1p, Gpm1p, Cdc19p, Pyc1p, Pyc2p, and Pdc1p) and the *HIS3* marker in the parent BY4741 strain were used to determine localization changes in proteins. *E. coli* was grown in lysogeny broth (1% (w/v) tryptone, 0.5% (w/v) yeast extract, 0.5% (w/v) sodium chloride, and 100 ng/mL ampicillin). The yeast cells were grown in yeast extract peptone dextrose (YPD) medium [1% (w/v) yeast extract, 2% (w/v) polypeptone, and 2% (w/v) glucose], YPD+G418 medium [YPD medium supplemented with 0.2 mg/mL G418], SDC+HM agar medium [0.67% (w/v) yeast nitrogen base without amino acids, 2% (w/v) glucose, 0.002% L-histidine-HCl, 0.003% L-methionine, 2% casamino acids (BD, Franklin Lakes, NJ, USA), and 2% (w/v) agar], SDC+HM medium [0.67% (w/v) yeast nitrogen base without amino acids, 2% (w/v) glucose, 0.002% L-histidine-HCl, 0.003% L-methionine, 2% casamino acids (BD), 50 mM MES, pH 6.0], or SC+ML medium [0.67% (w/v) yeast nitrogen base without amino acids, 2% (w/v) glucose, 0.003% L-methionine, 0.003% L-leucine, 0.13% SD Multiple drop out (-Ade, -His, -Leu, -Lys, -Trp, -Ura, Funakoshi Co., Ltd., Tokyo, Japan), and 2% (w/v) agar].

Construction of plasmids

All primers and plasmids used are described in Table 1. Plasmids pULI1 and pUL-ATG-EGFP were used both to adjust growth conditions of different cell types and as controls. To determine the amino acid residue important for foci formation by enolase (Eno2p), plasmids encoding Eno2p fragments and fragments carrying alanine substitutions (Table 1) were constructed. iProof DNA polymerase (Bio-Rad, Richmond, CA, USA), Ligation High (Toyobo, Tokyo, Japan), and synthetic oligonucleotides (Japan Bio Services, Saitama, Japan) were used for plasmid construction. DNA sequencing was performed using BigDye Terminator v3.1 Cycle Sequencing Kit and ABI PRISM 3100 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). All other chemicals were of analytical grade. The primers and restriction enzymes used are listed in Table 1. In brief, nucleotide sequences were amplified or mixed (for pUL-ATG-EGFP construction) and ligated with restriction fragments of plasmids [pULSG1 (Matsui et al. 2009) and pRS423 (ATCC), respectively].
**Plasmid transformation**
Yeast cells were transformed with plasmids using Frozen-EZ Yeast Transformation II™ kit (Zymo Research, Orange, CA, USA) and grown on SDC+HLM agar plates. Transformants were selected as single colonies and inoculated into 10 mL of SDC+HM medium with 50 mM MES (pH 6.0) for preculture at 25°C with shaking. At the late log phase, the preculture was subcultured in 100 mL of SD+HM medium at A600 = 0.01 and incubated at 25°C with shaking for 24 h. The culture was subcultured in 100 mL of SDC+HM medium with 50 mM MES (pH 6.0) at A600 = 0.1 for aerobic or semi-anaerobic (CO2 bubbled) culture at the indicated temperatures.

**Preparation of genomes**
Gentoru-kun High Recovery kit (Takara, Otsu, Shiga, Japan) was used to extract genomic DNA of GFP clones and yeast knockout mutants. The resulting genomes were used as templates for preparing nucleotide fragments to be transformed into cells.

**Construction of GFP-encoding yeast cells**
To construct a GFP clone of ENO2 containing the V22A substitution, an ENO2 knockout strain was constructed (Table 1). Oligonucleotide fragments containing ENO2-GFP-HIS3 and ENO2V22A-GFP-HIS3 were prepared (Fig. 1) and then inserted into the genome of the ΔENO2 strain at the position of ENO2. Yeast cells were transformed with nucleotide fragments and grown on SC+MLU agar plates. Single colonies were picked and again cultured on SC+ML or SC+MLU agar plates. The resulting cells were inoculated into SDC+HM media with 50 mM MES (pH 6.0) and cultured. Construction was confirmed by microscopic observation of fluorescence.

**Preparation of knock-out mutants of GFP clones**
Primers used are listed in Table 1. In this case, two methods were adopted. For the first, KanMX4-containing gene fragments were amplified from genomic DNA of yeast knockout mutant strains and transformed into yeast GFP clones. Transformants were cultivated on YPD+G418 agar plates, and resulting single colonies were again plated on SC+MLU+G418 agar media. For the second method, target gene fragments conjugated with GFP-HIS3 were amplified and transformed into knockout strains. Transformants were cultured on SC+MLU agar plates, and resulting single colonies were again plated on the same media. Constructed yeast strains were cultured in YPD+G418 liquid media and transformed with plasmid pUL11. Transformants were cultured on SDC+HM agar plates and the resulting colonies were used.

**Culture conditions**
For aerobic cultivation, a 500-mL Erlenmeyer flask with 100 mL of media was used. For
semi-anaerobic cultivation, a modified method of Katahira et al. (2006) was used. In brief, a culture vial with 100 mL media and stir bar was used. For introduction of CO₂ before cultivation, CO₂ was bubbled for 2 min into the media of the culture vial to remove DO. To provide air in the culture vial, a small air pump (Ei-bukubuku set; Kotobuki-kogei, Matsubara, Osaka, Japan) equipped with a needle-connected tube was used. For static culture, a test tube with 10 mL media was used. Yeast cells were cultivated at the indicated temperatures.

**Fig. 1 Preparation of fragments for integration of ENO2V22A-GFP** pro, promoter, term, terminator

**Treatments of cells with reagents**

Stock solutions of 100 mM farnesol and 1 mg/mL rapamycin (Santa Cruz Biotechnology, Santa Cruz, CA, USA) in ethanol and 1 mM oligomycin A (Sigma, St. Louis, MO, USA) and 10 mM rotenone (Sigma) in DMSO were prepared. To determine whether mitochondria participate in foci formation, CCCP (a mitochondria depolarizing agent) was used. A stock solution of 5 mM CCCP (Sigma) was prepared in ethanol and added to the media. Antioxidant NAC was directly added to the media.

**Fluorescence microscopy**

For confocal microscopy, cells were immediately fixed with 4% paraformaldehyde-containing PBS buffer for 1 h and observed. For observation of foci, the cells were immediately fixed or without fixation, immediately mounted on a glass slide and observed. For confocal microscopy, a Carl Zeiss LSM 700 laser scanning microscope (Carl Zeiss, Oberkochen, Germany) with a 60× objective (oil immersion NA, 1.35) and ZEN software were used. Otherwise, an epifluorescence microscope IX71 (Olympus, Lake Success, NY, USA) with a 100× objective (oil immersion NA, 1.40) and Aquacosmos software (Hamamatsu Photonics, Hamamatsu, Shizuoka, Japan) were used.
<table>
<thead>
<tr>
<th>Plasmid or genotype</th>
<th>Oligo name</th>
<th>Description</th>
<th>Sequence (5'-3')</th>
</tr>
</thead>
<tbody>
<tr>
<td>pUL-en0(30)</td>
<td>eno(1-8)</td>
<td>EcarF F</td>
<td>ACATAAAGAATTCATGCGCTTCTAAAGTATCACCGCT</td>
</tr>
<tr>
<td></td>
<td>eno(19-30),XhoI R</td>
<td></td>
<td>CAGATCCACCCCTCCAGAACAATCTTTTCGCTTGAATAGACCT</td>
</tr>
<tr>
<td>pUL-en0(30)</td>
<td>eno(1-8)</td>
<td>EcarR F</td>
<td>ATAAAAGAATTCATGCGCTTCTAAAGTATCACCGCT</td>
</tr>
<tr>
<td></td>
<td>eno(30),XhoI R</td>
<td></td>
<td>CAGATCCACCCCTCCAGAACAATCTTTTCGCTTGAATAGACCT</td>
</tr>
<tr>
<td>pUL-en0(30)</td>
<td>eno(1-8)</td>
<td>EcarF R</td>
<td>TAAACAGAATTCATGCGCTTCTAAAGTATCACCGCT</td>
</tr>
<tr>
<td></td>
<td>eno(30),XhoI R</td>
<td></td>
<td>CAGATCCACCCCTCCAGAACAATCTTTTCGCTTGAATAGACCT</td>
</tr>
<tr>
<td>pUL-en0(30)</td>
<td>eno(1-8)</td>
<td>EcarR R</td>
<td>TAAACAGAATTCATGCGCTTCTAAAGTATCACCGCT</td>
</tr>
<tr>
<td></td>
<td>eno(30),XhoI R</td>
<td></td>
<td>CAGATCCACCCCTCCAGAACAATCTTTTCGCTTGAATAGACCT</td>
</tr>
</tbody>
</table>

Table 1: Primers used in CHAPTER II

- **Primers for cloning EN02 fragments**
- **Primers for introducing amino acid substitution**

**Note:**
- Primers are designed for specific restriction sites and sequences as indicated.
Table 1 Primers used in CHAPTER II (continued)

<table>
<thead>
<tr>
<th>Primers</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>pUL-ADH</td>
<td>Primer for sequencing primer for sequencing p413pADH and p416-ADH plasmids</td>
</tr>
<tr>
<td>pUL-ATG</td>
<td>Primers for amplification of SNF1 (forward)</td>
</tr>
<tr>
<td>pUL-FLAG</td>
<td>Primers for amplification of SNF1 (reverse)</td>
</tr>
<tr>
<td>Xho-FLAG</td>
<td>Primers for forming FLAG sequence by OSCOM</td>
</tr>
<tr>
<td>E2-URA3</td>
<td>Primers for introducing URA3 instead of E2O2</td>
</tr>
<tr>
<td>E2-o26:Oligo1</td>
<td>Primers for checking URA3</td>
</tr>
<tr>
<td>E2-o26:Oligo2</td>
<td>Primers for introducing kanMX4 instead of E2O2</td>
</tr>
<tr>
<td>E2-202G</td>
<td>Primers for introducing E2O2-GFP instead of E2O2</td>
</tr>
<tr>
<td>E2-o26:GFP-His3</td>
<td>Primers for cloning E2O2 from genome and for sequencing</td>
</tr>
<tr>
<td>E2-o26:222A</td>
<td>Primers for introducing V22A substitution</td>
</tr>
<tr>
<td>E2-o26:GHO1</td>
<td>Primers for checking genotype</td>
</tr>
<tr>
<td>E2-o26:SNF1</td>
<td>Primers for checking genotype</td>
</tr>
<tr>
<td>E2-o26:SCH9</td>
<td>Primers for checking genotype</td>
</tr>
</tbody>
</table>
**pH and DO measurement**

pH measurement of culture media was performed using a F-52 pH meter (Horiba, Kyoto, Japan). Time course measurement of DO (mg/L) was performed using a luminescent DO (LDO) meter (HQ30d; Hach Co., CO, USA). Measurements were recorded automatically every 15 min for 8 h. As an indicator of anoxia, 1 mg/mL stock solution of resazurin (Sigma) was added to the media to a final concentration of 1 μg/mL to make a blue-colored solution. Under anoxia, the resazurin-containing media has no color, while under hypoxia, it turns red.

**FACS analysis**

Cells were suspended in PBS and assayed immediately using a cell sorter (JSAN, Bay Bioscience, Kobe, Hyogo, Japan) using the detection channel FLT1 (535DF45). In each case, the fluorescence of 10,000 cells was acquired.

**Sample preparation of yeast proteins for proteomic analysis**

*S. cerevisiae* BY4741 strains transformed with pYEX-ENO2G or pYEX-ENO2V22AG were cultivated aerobically or semi-anaerobically at 30°C. The cells were lysed as described above, and proteins were extracted. Protein purification was performed as follows:

250 μL of 25 mM Tris-HCl buffer (pH 7.8) was added to frozen cells. After homogenization for 3 times at 4,000 rpm for 60 sec using glass beads (GB-05, diameter 0.5 mm; TOMY, Tokyo, Japan) and Bead Smash 12 (Wakenyaku, Kyoto, Japan), the sample solutions were centrifuged at 9,700 g for 5 min at 4°C. Aliquots (500 μL) of the supernatants were filtrated using 0.45 μm spin column filter membrane (Durapore PVDF membrane; Millipore, Eschborn, Germany) and set still on ice. Purification of proteins was carried out immediately after extraction of proteins using ANTI-FLAG M2 affinity gel (Sigma) and column (Poly-Prep Chromatography Columns; Bio-Rad) following the manufacturer's protocol. After purification, samples were washed with 20 mM triethylammonium bicarbonate using Microcon YM-3 concentrator (Millipore).

The collected proteins were reduced with 10 mM tris(2-carboxyethyl)phosphine (Thermo Scientific) for 30 min and alkylated with 20 mM iodoacetamide (Thermo Scientific) for 60 min in the dark at room temperature. After acetone precipitation, the proteins were solubilized in 200 mM triethylammonium bicarbonate (Sigma). Protein digestion (trypsin:protein = 1:50) was performed overnight at 37°C. Tryptic digests were applied to a proteome analysis system.

**Liquid chromatography–tandem mass spectrometry (LC-MS/MS) analysis and MS data analysis**

Protein identification was performed with a liquid chromatography/mass spectrometry system as described in (Aoki et al. 2012). Proteolytic digests were separated by reversed-phase
chromatography using a UltiMate3000 nano LC system (Dionex). A monolithic silica capillary column (200 cm long, 0.1 mm i.d.) prepared with a mixture of tetramethoxysilane and methyltrimethoxysilane was used at a flow rate of 500 nL/min. The gradient was provided by changing the mixing ratio of the 2 eluents: A, 0.1% (v/v) formic acid and B, 80% acetonitrile containing 0.1% (v/v) formic acid. The gradient was started with 5% B and increased to 50% B for 600 min. The separated analytes were detected on an LTQ Velos linear ion trap mass spectrometer (Thermo Scientific). An ESI voltage of 2.4 kV was applied directly to the LC buffer distal to the chromatography column using a microtee. The ion transfer tube temperature on the LTQ Velos ion trap was set to 300°C. For data-dependent acquisition, the method was set to automatically analyze the five most intense ions observed in the MS scan. The mass spectrometry data were used for protein identification by the Mascot search engine on Protein Discoverer software (Thermo Scientific) against the information in the Saccharomyces Genome Database (SGD; http://www.yeastgenome.org). Search parameters for peptide identification included a precursor mass tolerance of 2.2 Da, a fragment mass tolerance of 0.8 Da, a minimum of one tryptic terminus, and a maximum of one internal trypsin cleavage site. Cysteine carbamidomethylation (+57.021 Da) and methionine oxidation (+15.995 Da) were set as a differential amino acid modification. The data were then filtered at a q value $\leq 0.01$ corresponding to 1% FDR at the spectral level, and identified proteins coimmunoprecipitated with Eno2p-EGFP-FLAG-tag contained $\geq 4$ peptide fragments.

**Extraction of cellular metabolites**

Cellular metabolites were extracted by modified methods of Mashego et al. (2003). Cells incubated at 30°C in 500 μL media containing [U-13C]-glucose for 0, 2, 5, and 10 min were immediately injected into 5 mL of 60% methanol at −40°C. After centrifugation at 5,000 ×g at −9°C for 5 min, the supernatants were discarded and 3 mL of 75% ethanol was added. After heating at 100°C for 30 min and cooling on ice and then at −40°C, the cells were lyophilized and stored at −80°C. For sample preparation, 1 mL of MilliQ and 60 μL of 0.2 mg/mL ribitol were added to lyophilized cells and heated at 37°C for 30 min in a 1.5 mL test tube. The samples were then centrifuged at 16,000 ×g for 5 min at 4°C, 900 μL of supernatant was transferred to a new tube, 400 μL of MilliQ was added to each sample followed by centrifugation at the same rate, and 400 μL of supernatant was transferred to a new tube, lyophilized, and used for metabolite analysis.

Extracted metabolites were derivatized as described (Tsugawa et al. 2011). For oximation, 100 μL of methoxyamine hydrochloride in pyridine (20 mg/mL) was added and incubated at 30°C for 90 min. For trimethylsilylation, 50 μL of N-methyl-N-(trimethylsilyl) trifluoroacetamide was added, followed by incubation at 37°C for 30 min. Insoluble residue was removed by centrifugation at, 10,000 ×g for 10 min at 4°C, and the supernatant was transferred to a clean vial.
**GC/MS analysis**

Derivatized metabolites were analyzed using GCMS-QP2010 Ultra (Shimadzu, Kyoto, Japan) equipped with a 30 m × 0.25 μm i.d. fused silica capillary column coated with 0.25-μm CP-SIL 8 CB low bleed (Agilent Technologies, Palo Alto, CA, USA). Aliquots of 1 μL were injected in split mode (25/1, split mode) at 230°C using helium as carrier gas at a flow rate of 1.12 mL/min. The column temperature was held at 80°C for 2 min isothermally, then raised at 4°C/min to 130°C, and then raised at 25°C/min to 330°C and held for 6 min isothermally. Interface and MS source temperatures were 250°C and 200°C, respectively, and ion voltage was 1 kV. Data were collected by GC-MS solution software (Shimadzu), and identified metabolites are shown in Table 2. Mass isotopomer distributions were corrected for natural isotope abundance as described (Nanchen et al. 2007).

<table>
<thead>
<tr>
<th>Name</th>
<th>Retention time (min)</th>
<th>Formula</th>
<th>m/z range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pyruvate &amp; Oxaloacetate</td>
<td>4.63</td>
<td>C₆H₁₂NO₃Si</td>
<td>174-177</td>
</tr>
<tr>
<td>Alanine</td>
<td>7.57</td>
<td>C₉H₂₀NO₂Si₂</td>
<td>218-221</td>
</tr>
<tr>
<td>Glycerol</td>
<td>13.20</td>
<td>C₁₂H₂₇O₅Si₃</td>
<td>335-339</td>
</tr>
<tr>
<td>Malate</td>
<td>17.29</td>
<td>C₁₂H₂₇O₅Si₃</td>
<td>335-339</td>
</tr>
<tr>
<td>Aspartate</td>
<td>17.60</td>
<td>C₉H₂₂NO₂Si₂</td>
<td>232-235</td>
</tr>
<tr>
<td>PEP</td>
<td>18.27</td>
<td>C₁₁H₂₉O₆PSi₃</td>
<td>369-372</td>
</tr>
</tbody>
</table>
Section 1  Determination of foci-forming region of enolase

**Determination of the region of Eno2p that is sufficient for foci formation**
To determine the key residue for foci formation by Eno2p, the N-terminal foci-forming Eno2p region was investigated. The shortest foci-forming region of N-terminal Eno2p fused with EGFP was amino acid residues 5–24 (Fig. 2). Foci-forming cells increased when the amount of proteins increased, while still there were foci-forming cells with few proteins (Fig. 3).

**Determination of important amino acid residues for foci formation by single alanine substitution**
In amino acid residues 6–23, alanine substitution of V22 inhibited foci formation (Fig. 4).

**Amino acid substitution of V22 residue to gain information on the role of V22**
Substitution of V22 with A, P, E, D, S, T, R, H, K, and N also inhibited foci formation by the N-terminal region, while substitution with L, I, Y, and W conserved foci (Fig. 5).

**Effects of foci-inhibiting V22A substitution on secretion of Eno2p**
To test whether the foci forming property of Eno2p correlates secretion, secretion of V22A substituted proteins of both N-terminal region and full length Eno2p were investigated. As the result, substitution of V22 to alanine didn’t inhibit secretion of both N-terminal region of and full length Eno2p (Fig. 6).

---

**Fig.2** Determination of the foci-forming region of N-terminal Eno2p conjugated with EGFP and a FLAG tag. pUL-eno(X-Y): cells transformed with plasmids pUL-eno(X-Y). pUL-eno(5–25)+GGS: cells transformed with plasmid pUL-eno(5–25)+GGS. Cells were aerobically cultivated and observed.
Fig. 3 Protein amount-dependent changes in the proportion of foci-forming cells. A: Illustration of the plasmid used. B: Time- and Cu$^{2+}$-dependent fluorescence induction. The number off the line indicate the concentration of CuSO$_4$ [µM] in the reaction solution. C: Percentage of foci-forming cells. D: Images of foci forming cells.

<table>
<thead>
<tr>
<th>Copper ion [µM]</th>
<th>foci-forming cells</th>
<th>counted cells</th>
<th>% foci-forming cells</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>2</td>
<td>412</td>
<td>0.5</td>
</tr>
<tr>
<td>1</td>
<td>3</td>
<td>298</td>
<td>1.0</td>
</tr>
<tr>
<td>2</td>
<td>3</td>
<td>1288</td>
<td>0.2</td>
</tr>
<tr>
<td>5</td>
<td>2</td>
<td>222</td>
<td>0.9</td>
</tr>
<tr>
<td>10</td>
<td>8</td>
<td>279</td>
<td>2.9</td>
</tr>
<tr>
<td>50</td>
<td>2</td>
<td>163</td>
<td>1.2</td>
</tr>
<tr>
<td>100</td>
<td>10</td>
<td>137</td>
<td>7.3</td>
</tr>
<tr>
<td>200</td>
<td>21</td>
<td>205</td>
<td>10.2</td>
</tr>
<tr>
<td>500</td>
<td>14</td>
<td>26</td>
<td>53.8</td>
</tr>
</tbody>
</table>

Fig. 4 Single alanine substitution of N-terminal amino acids of Eno2p conjugated with EGFP and FLAG. pUL-eno(30): cells transformed with plasmid pUL-eno(30). XxA: cells transformed with plasmids pUL-eno(30)XxA.
Fig. 5 Amino acid substitutions of Val22 residue. A: Illustration of pUL-eno(30) and the mutated residues. B: Fluorescence images. V22X: cells transformed with plasmid pUL-eno(30) V22X in which the Eno2p N-terminal (1–30) amino acid sequences with V22X substitution were conjugated with EGFP and a FLAG tag.

Conservation of the foci-forming ability
Conservation of the foci-forming ability of the N-terminal region was further investigated. The N-terminal region of Eno2p is conserved across species (Fig. 7A). In *Escherichia coli* enolase, although V22 was not conserved, the N-terminal region conserved the foci-forming ability. In contrast, in mouse β- and γ-enolase, the foci-forming ability was lost although V22 residues were conserved. Interestingly, mouse α-enolase retained the foci-forming ability (Fig. 7B). These results suggest that the foci-forming ability of the N-terminal region of Eno2p is conserved over species but is not always dependent on V22.
Fig. 6 Effects of V22A substitution on secretion of Eno2p. Positive cont.: secreted proteins from cells transformed with pULSG1C. Negative cont.: secreted proteins from cells transformed with pULI1. pUL-X: secreted proteins from cells transformed with pUL-X plasmids.

Discussion

Val 22 and foci forming (5-25) amino acid residues is located in the N-terminal beta-hairpin forming region in Eno2p (Fig. 8). Amino acids V, I, L, Y, and W, which supported the foci-forming ability at amino acid 22 in the N terminus, have also been reported to be important in stacking of β-hairpin structures of tau proteins (Margittai and Langen 2006). Accordingly, the three-dimensional structure of the N-terminal Eno2p region might be important in forming foci. Spatial rearrangement of the specific amino acid sequence of Eno2p may promote the spatial rearrangement of the whole protein (Fig. 9).
Fig. 7 Conservation of primary sequence and foci-forming properties of N-terminal region of enolases. A: Sequence alignment of N-terminal amino acids of Eno2p. B: Foci formation of N-terminal fragments of enolases conjugated with EGFP and a FLAG tag. Cells transformed with plasmids for producing N-terminal amino acid sequences of enolases conjugated with EGFP and a FLAG tag are shown.
Fig. 8 Three-dimensional structures of N-terminal (1-30) region of Eno2p. Red: positively charged amino acid residues. Blue: negatively charged amino acid residues. Yellow: important amino acid residues for foci formation. PDB ID: 1one.

Fig. 9 Suggested roles of N-terminal region of Eno2p on unknown moonlighting functions. Sun: previously known function of moonlighting proteins. Moon: moonlighting functions. Dotted circle: suggested areas of proteins responsible for the function indicated by arrows.
Section 2  Discovery of foci-formation of full-length enolase under hypoxia

Discoveries of changes in localization of glycolytic enzymes including Enolase, conjugated with EGFP, which are overproduced by plasmids in *S. cerevisiae* BY4741 wt cells

*S. cerevisiae* B4741 wt strains transformed with plasmids for overexpressing proteins of glycolytic enzymes conjugated with EGFP and a FLAG-tag formed concentrated EGFP in static culture (Fig. 10).

![Image of localization of EGFP fluorescence conjugated with glycolytic enzymes](image)

**Fig. 10** Localization of EGFP fluorescence conjugated with glycolytic enzymes after static culture. Cells transformed with PULGI2-X plasmids are shown (X: each name represented in the figure).

Foci-formation of GFP-conjugated metabolic enzymes under hypoxia

Fermentation vials were used to culture cells under semi-anaerobic (hypoxic) conditions (Fig. 11). A GFP clone in which *ENO2* is fused with *GFP* (ENO2-GFP strain) formed foci under fermentative conditions after 6 h of culture in vials at 30°C (Fig. 11A). Foci formation by the glycolytic enzymes Cdc19p, Gpm1p, Pfk1p, Gpd1p, Ald4p, and Tdh3p under hypoxia was also observed (Fig. 11B).
Fig. 11 Foci formation of glycolytic enzymes under hypoxia. A: Foci formation of ENO2-GFP strain under semi-anaerobic culture at 30°C. Bar = 10 µm. B: Foci formation of other metabolic enzymes. C: Summary of the foci-forming enzymes. Green letters indicate foci-formed proteins. Gray letters indicate investigated proteins that didn’t form foci.

Time- and temperature-dependent foci formation of Eno2p-GFP
Foci formation of Eno2p was dependent on temperature and time. At 30°C, foci were formed after 6 h of semi-anaerobic cultivation, while in 37°C, foci were formed after 3 h of semi-anaerobic cultivation. At 25°C, interestingly, foci weren’t formed after 12 h of semi-anaerobic culture (Fig. 12).

Measurements of pH and DO changes during the course of foci formation
During cultivation, pH did not fall below 5 in both CO2-bubbled (Fig. 13A) and non-bubbled (Fig. 13B) vials. In CO2-nonbubbled vials, DO decreased more rapidly at 37°C than at 30°C and 25°C, while in air-bubbled vials, DO remained at normoxic level after 8 h of cultivation (Fig. 13C). After 6 h of culture in vials at 30°C, the color of resazurin added to media was still pink, indicating there were some amount of oxygen in the vial (Fig. 13D).

Inhibition of foci formation by V22A substitution of Eno2p-GFP
After 12 h of culture in vials at 30°C, the V22A mutant of ENO2-GFP (ENO2V22A-GFP strain) did not form foci (Fig. 14).
Fluorescent foci formed by DsRED-conjugated N-terminal Eno2p were colocalized with foci of the ENO2-GFP strain at 30°C after 6 h of fermentative culture (Fig. 15).

**Fig. 12 Time-and temperature-dependent foci formation by Eno2p-GFP under hypoxia.** Time-dependent foci formation of ENO2-GFP strain at indicated temperatures (A: 30°C, B: 37°C, and C: 25°C) are shown.
Fig. 13 pH and DO changes in the vials. A and B: changes in pH inside the culture vial with (A) or without (B) CO₂ bubbling before culture are shown. C: Time-and temperature-dependent DO changes without bubbling CO₂ before culture. D: DO changes represented by color changes of resazurin. Clear color shows anoxia.
Fig. 14 Effects of substitution of Eno2p sequence on foci formation. Cells grown at 30°C in aerobic or anaerobic culture for 12 h. ENO2G: ENO2-GFP strain. eno2::ENO2V22A: V22A mutation introduced in ENO2 sequence of ENO2-GFP strain. Bar = 10 µm.

Fig. 15 Colocalization of the foci. N-terminal foci formation and (Red) and foci formation of full length Eno2p (Green) are shown.

Discussion
Spatial rearrangement of glycolytic enzymes including Eno2p was detected for the first time in S. cerevisiae under hypoxic fermentation culture. The novel intercellular localization changes detected may enable glycolytic proteins to perform unknown moonlighting functions in response to specific environmental stimuli. Given that S. cerevisiae has many biological processes in common with other eukaryotic cells, these changes may be conserved over species. Regulation of several proteins participating sequentially in a metabolic pathway by spatial reorganization would be an important and effective method of regulating cellular processes. Colocalization of foci formed by full-length Eno2p-GFP and an N-terminal fragment fused with DsRED (Fig. 15) supported the speculation that
an N-terminal foci-forming region regulates spatial rearrangement of full-length Eno2p. I concluded that spatial rearrangement of the specific amino acid sequence of Eno2p promoted the spatial rearrangement of the whole protein. Screening peptide sequences would be a useful approach for discovering such amino acid sequences in other foci-forming proteins under hypoxia.
Section 3  Regulatory mechanisms of foci-formation of enolase

Results

Temperature-independent inhibition of foci formation by cycloheximide and rapamycin

Foci formation by Eno2p-GFP was inhibited by cycloheximide at 30°C and 37°C in semi-anaerobic culture (Fig. 16A). On application of a growth-inhibiting dose of farnesol, an inhibitor of the cAMP, PKA, and MAPK signaling pathways in C. albicans (Sato et al. 2004, Rhome et al. 2009, Cho et al. 2010, Deveau et al. 2010) and a mitochondrial ROS generator (Machida et al. 1998) and growth inhibitor (Machida et al. 1999) in S. cerevisiae, foci formation was conserved (Fig. 16B). In contrast, rapamycin at a growth-inhibiting dose inhibited foci formation at 37°C (Fig. 16B, C). These results suggest the DO-independent participation of both de novo protein synthesis and TORC1-dependent regulation at 37°C in foci formation.

Identification of SNF1 as a regulator of foci formation at 30°C

To determine the signaling pathway regulating foci formation, knockout mutations of genes participating in signaling pathways, namely HOG1 (MAPK pathway), SCH9 (PI3K-AKT pathway), and SNF1 (SNF1/AMPK pathway) were introduced into the ENO2-GFP strain. In semi-anaerobic culture, foci formation by the ENO2-GFP strain without SNF1 (ΔSNF1 ENO2-GFP strain) was inhibited at 30°C, while the other strains formed foci (Fig. 17A, B). To assess the involvement of Upc2p, which is a known regulator of hypoxia-responding transcription factor in yeast C. albicans (Synnott et al. 2010) and S. cerevisiae (Siso et al. 2012), a UPC2 knockout mutation was introduced in the same manner. Foci formation was not inhibited, suggesting no involvement of Upc2p in foci formation under hypoxia (Fig. 17A). At 37°C in semi-anaerobic culture, the ΔSNF1 ENO2-GFP strain formed foci (Fig. 17C). A strain with plasmid-reintegrated SNF1 regained the foci-forming ability under semi-anaerobic culture at 30°C (Fig. 17D), showing the participation of SNF1 in foci formation at 30°C. These results suggested that foci were formed at 30°C in response to hypoxia by participation of SNF1/AMPK. In general, the optimum temperature for cultivating the S. cerevisiae BY4741 strain is 30°C. We accordingly focused on foci formation induced at 30°C under hypoxia and by involvement of SNF1/AMPK.

Involvement of mitochondrial ROS production in foci formation

The involvement of mitochondrial ROS production, which is known to activate AMPK, was investigated using mitochondrial inhibitors and an antioxidant (Fig. 18A). The mitochondrial uncoupler carbonyl cyanide m-chlorophenylhydrazone (CCCP) inhibited foci formation, indicating mitochondrial involvement (Fig. 18B). Oligomycin A and antimycin A, inhibitors of mitochondrial ATPase and complex III, respectively, also inhibited foci formation. The antioxidant
N-acetyl-L-cysteine (NAC) inhibited foci formation, indicating the involvement of mitochondrial ROS release to the cytoplasm under hypoxia (Fig. 18C).

**Fig. 16** Inhibition of foci formation by Eno2p with cycloheximide and rapamycin. A: Inhibition by the addition of cycloheximide and B: rapamycin. C: Growth inhibition by the addition of rapamycin and farnesol. For A, after 3 or 6 h of cultivation at indicated temperatures, ENO2-GFP cells transformed with PUL1 were observed. Each media contains cycloheximide. For B: After 12 h of semi-anaerobic culture at 37°C containing farnesol or rapamycin at indicated dose, cells were harvested and observed. Growth curves show A600 of media containing indicated doses of reagents. RAPA: rapamycin. Bar = 10 μm.
Fig. 17 Foci formation and its dependency on SNF1. A: ENO2-GFP strains with or without HOG1 or UPC2 knockout mutation. B: ENO2-GFP strains with or without SNF1 knockout mutation. Each strain contains plasmid pUL11 or indicated plasmid. C: Foci formation by SNF1 knockout mutant at 37°C. D: Plasmid reintegration of SNF1. Bar = 10 µm.
Fig. 18 Inhibition of foci formation by antioxidant and inhibitors for mitochondrial ROS production at 30°C A: Schematic illustration of inhibiting ROS produced by mitochondria (modified from Harrero et al. 2008 and Clémençon 2012). B: Inhibition by CCCP. C: Inhibition of foci formation by adding mitochondrial inhibitors and antioxidant.
Discussion

Temperature-independent inhibition of foci formation by cycloheximide suggested that de novo protein synthesis is an important factor, in addition to regulation by the signaling pathway. Although inhibition of foci formation by rapamycin was temperature independent, the doses of rapamycin added to cells that allowed inhibition of foci formation inhibited cell growth. This suggests that regulation by TORC1 occurs before de novo protein synthesis. However, TORC1 incorporation is important, given that foci formation was not inhibited when farnesol was added at a growth-inhibiting dose. The finding that HOG1 and SCH9 knockout failed to inhibit foci formation is reasonable, given that farnesol is reported to be an inhibitor of the MAPK and PKC/Akt pathways in the pathogenic fungus C. albicans (Synnott et al. 2010).

Inhibition of foci formation by SNF1 knockout was unexpected, given that the SNF1/AMPK pathway is known to be activated by a glucose-limiting state in which glycolytic enzymes are downregulated. However, the inhibition of foci formation by mitochondria inhibitors and antioxidant supported SNF1/AMPK involvement in hypoxia-responsive foci formation. Foci formation was strongly dependent on heat and decreased DO in culture media. These results suggest that foci formation by Eno2p was dependent on more than one pathway. Although AMPK is known to inhibit the TOR pathway (Hardie 2011), there are some instances in which both the AMPK and TOR pathways regulate cell physiology (Hardie 2011). For example, in S. cerevisiae, both Snf1p and TORC1 have been suggested to have roles in regulation of fatty acids by unknown mechanisms (Zhang et al. 2011). The unknown regulatory mechanisms for these two pathways await discovery by future studies.
Section 4  The effects of foci on cellular carbon metabolism

Foci formation of plasmid-reintroduced Eno2p-EGFP-FLAG in BY4741ΔENO2 cells
To detect proteins involved in foci formation, an ENO2 knockout (ΔENO2) strain and plasmids for production of recombinant Eno2p-EGFP-FLAG protein or its V22A mutant (Eno2V22Ap-EGFP-FLAG) were prepared. The fluorescence intensities of ΔENO2 strains producing recombinant proteins were similar to those of the ENO2-GFP strain in aerobic culture (Fig. 19A). After 12 h of semi-anaerobic culture, the Eno2p-EGFP-FLAG protein formed foci (Fig. 19B).

Fig. 19 foci formation of plasmid-reintroduced Eno2p-EGFP under hypoxia. A: Fluorescence intensities of each strain measured by FACS. B: Foci formation of plasmid-reintroduced Eno2p-EGFP in ΔENO2 strains. Bar = 10 μm.

Detection of coimmunoprecipitated proteins with foci-forming Eno2p
To investigate proteins associating with foci-forming Eno2p, Eno2p-EGFP-FLAG and Eno2V22Ap-EGFP-FLAG proteins were immunoprecipitated and identified by LC/MS/MS (Fig. 20A). As a result, 80 proteins including 43 metabolic proteins were detected in proteins coimmunoprecipitated with Eno2p-EGFP-FLAG (Fig. 20B). Of these, two proteins, Shm2p and Ade5,7p, were detected only in the proteins coimmunoprecipitated with Eno2p-EGFP-FLAG (Fig. 20C).
Fig. 21 Changes in carbon metabolic pathway of foci-carrying cells. A: Retention of the foci under aerobic culture. B: Scheme for measurement of incorporated $^{13}$C in metabolites. C: Incorporation of $^{13}$C derived from glucose into metabolites of foci forming and nonforming cells. Red line: metabolites extracted from cells after aerobic culture. Blue line: metabolites extracted from cells after anaerobic culture. Red line: metabolites extracted from cells after aerobic culture. Blue line: metabolites extracted from cells after anaerobic culture.
Investigation of the effects of foci-inhibiting mutations in hypoxia-treated cells on the carbon metabolic pathway by metabolic turnover analysis

In the ENO2-GFP strain, after semi-anaerobic culture for 6 h, foci were retained following 24 h of aerobic culture in fresh media (Fig. 21A). To investigate the effects of foci on cellular carbon metabolism, metabolic turnover analysis using [U-13C]-glucose after semi-anaerobic (foci-forming condition) or aerobic (foci-non-forming condition) culture was measured using the ENO2-GFP and ENO2V22A-GFP strains (Fig. 21B). The ratio of 13C-containing pyruvate and oxaloacetate were higher in foci-forming than in foci-non-forming cells after 2 and 5 min of intake (Fig. 21C). For glycerol and alanine, in the ENO2V22A-GFP strain, the ratios of 13C-containing metabolites were slightly higher in cells under anaerobic culture, whereas the ratio remained unchanged in the ENO2-GFP strain. These results suggested that cells carrying foci accelerated the incorporation of glucose-derived 13C into pyruvate and oxaloacetate and preferentially produced aspartate and malate, rather than glycerol or alanine, from pyruvate.

Discussion

The organism's ability to switch the carbon metabolic pathway is considered important for controlling energy flow and synthesis of cellular components. Given that the glycolytic pathway has many branches connected to various metabolic pathways including nucleotide, amino acid, and lipid synthesis and energy production, effective use of carbon sources according to cellular needs in various situations is expected to be extremely important in the struggle for survival. Regulation of the carbon metabolic pathway has been reported to be accomplished by transcriptional regulation of various regulators (Daran-Lapujade et al. 2004). With respect to switching the carbon metabolic pathway in proliferating mammalian cells, p53 is known to target the TP53-induced glycolysis and apoptosis regulator and synthesis of cytochrome c oxidase, leading to glycolysis inhibition and a shift to oxidative phosphorylation (Bensaad et al. 2006, Matoba et al. 2006, Jones and Thompson 2009). It has not been reported that the central carbon metabolic pathway could be regulated by spatial reorganization or association of glycolytic enzymes.

Foci formation by Eno2p and other glycolytic enzymes conjugated with GFP under hypoxia (Fig. 5, S5) suggests the formation of a compartment of glycolytic enzymes in the cytosol. As predicted by a simulation study of glycolytic flux, under foci-forming conditions, incorporation of glucose-derived 13C into pyruvate and oxaloacetate was accelerated. Inhibition of foci formation by introduction of the V22A mutation canceled out the effect, demonstrating the participation of foci formation by Eno2p in controlling carbon metabolism. Moreover, the increased ratio of 13C-containing glycerol and alanine in foci-non-forming cells suggest that foci are needed to accelerate a specific branch of glycolysis. Thus, these results support a hypothesis that under
hypoxia, certain glycolytic enzymes are spatially reorganized to alter the carbon metabolic pathway. Fluxes and concentrations of metabolites in glycolysis are rapid and small, especially in reactions catalyzed by Eno2p, although Eno2p is one of the most abundant proteins in the cell. However, changing the amount of Eno2p seems to have no significant effect, as indicated by results in *E. coli* (Usui et al. 2012). Under hypoxia in *S. cerevisiae*, the amounts of Eno2p and other glycolytic enzymes reportedly increased significantly (de Groot et al. 2007). Controlling protein concentrations would be a reasonable and effective method to switch the carbon metabolic pathway.

In addition to the hypoxic state, higher temperatures of 37°C induced foci formation by Eno2p. The association of temperature and the hypoxic state in inducing foci formation remains unclear. The finding that foci formation at 37°C was inhibited by the addition of cycloheximide or rapamycin but not by *SNF1* knockout mutation suggests that there are two ways of regulation: by oxygen concentration and by temperature increase. Postmas et al recently reported that glycolytic flux increases in fermenting *S. cerevisiae* at 38°C (Postmus et al. 2012). They showed that increased activity of glycolytic enzymes did not correlate with protein abundance and suggested the contribution of post-translational regulation to enzyme activity. Foci formation by glycolytic enzymes is a seemingly efficient method of regulating glycolytic enzymes post-translationally.

The important amino acid residues or domains for foci formation by each enzyme could be determined in the manner we have demonstrated for Eno2p. Control of the carbon metabolic pathway in proliferating cells is an important issue. Eno2p and other glycolytic enzymes are overproduced in tumor cells in which the glycolysis rate is increased. If spatial reorganization of glycolytic enzymes occurs in mammalian cells, the results and methods demonstrated in this study could contribute to the control of carbon metabolism in proliferating cells including tumor cells.

![Fig. 22 Schematic illustration of the proposed regulation and the biological role of foci formation](image-url)
Shifting metabolic pathways by forming protein complexes is an attractive strategy. In *Saccharomyces cerevisiae*, we found that glycolytic enzymes, including enolase (Eno2p), conjugated with GFP formed cellular foci under hypoxia. Foci formation by Eno2p was inhibited temperature independently by the addition of cycloheximide or rapamycin or by single alanine substitution of the Val22 residue. Using mitochondrial inhibitors and an antioxidant, mitochondrial ROS production was shown to participate in foci formation at 30°C. Foci formation was also inhibited at 30°C by an *SNF1* knockout mutation. Foci were observed in the cell after reoxygenation. Metabolic turnover analysis revealed that [U-13C]-glucose was assimilated into pyruvate and oxaloacetate in shorter time in foci-forming than in -non-forming cells. These results suggest that under hypoxia, *S. cerevisiae* senses mitochondrial ROS by activating SNF1/AMPK and spatially reorganizes some metabolic enzymes in the cytosol via *de novo* protein synthesis, thereby contributing to an altered carbon metabolic pathway (Fig. 22).

**References**

CHAPTER III

Development of a novel method and an instrument to validate intracellular roles of extracellular moonlighting proteins

Introduction

Secretion and surface localization of enolase have been found (see Chapter I). Yet, the roles and the mechanisms of function of secreted or surface-localized enolase in S. cerevisiae are not known. To uncover these, the system for experimental re-construction and investigation of cell-cell interaction by designed proteins should be developed. Here, the concept of a novel co-cultivation based method that is to observe changes of cells when co-cultivated with genetically-modified (GM) cells to produce effector proteins arose. While enolase is known to localize cellular surface of many organisms, the mechanisms of surface localization is not known. Therefore, well-known proteins that bind cellular surface should be selected to construct the model system.

Previously, Bosma et al. (2006) developed a method to display recombinant proteins on the non-GM gram-positive bacterial cell surface. They used the bacterial LysM domain (Pfam accession number PF01476) as a microbial-surfacebinding domain and non-GM gram-positive bacterial cells named gram-positive enhancer matrix particles as scaffolds to generate a non-GM vaccine (Bosma et al. 2006; van Roosmalen et al. 2006). However, the method includes chemical pretreatment of non-GM cells. The treatment kills bacteria, and it was impossible to investigate living bacterial functions such as multiple metabolic pathways and mobility. To use various native functions of bacteria, there is a need to develop a non-GM display system of living cells without chemical pretreatment. On the other hand, our system is different from previously reported system in the following points: this is a non-GM display system for living microorganisms without chemical pretreatment, and we used the lectin module, which is present in a broad range of species, as a binding module.

The C-type lectin-like domain (CTLD, InterPro entry accession number IPR16186) and LysM domain are cell wall-recognition domains, but their three-dimensional structures and determined binding substrates are different. The LysM domain has a distinctive αββα fold and has no similarity to other carbohydrate-binding modules (Bateman and Bycroft 2000). The fold includes a shallow groove formed by two helixes and two loops (Ohnuma et al. 2008). The groove has a cluster of hydrophobic residues, and by the participation of the groove, the LysM domain binds β-1,4-linked N-acetylglucosamine (chitin) oligosaccharides ((GlcNAc)n) (Ohnuma et al. 2008). LysM can recognize fungal cell wall (Wan et al. 2008) and bacterial cell wall peptidoglycans and the Nod receptor to initiate nodulation in the case of Rhizobium (Radutoiu et al. 2007). CTLD has a double-loop structure on both sides of antiparallel β-sheet (Zelensky and Gready 2005) to form a carbohydrate-binding site called the SPD (surfactant protein D) cleft (Hallman and Haataja 2006).
The cleft involves hydrophobic residues and has a Ca\(^{2+}\)-binding site. At this site, CTLD binds to various mono- and oligosaccharides or carbohydrate chains in a Ca\(^{2+}\)-dependent manner. In this study, we constructed a non-GM display system using one of the microbial-surface-binding domains, CTLD from human surfactant protein D (SP-D, Protein Data Bank accession number 1PWB), without chemical treatment.

Figure 1 shows a model of a newly constructed system to investigate intercellular roles of moonlighting proteins. In this model system termed the “molecular sniping and shooting method (MSSM),” target proteins fused with the yeast-cell-surface-binding motif are produced in GM yeast and secreted. The mechanism for the protein-targeting system to bind proteins to the co-cultivated non-GM yeast surface is based on the property of the binding motif and cell-surface carbohydrates. GM and non-GM yeasts were co-cultivated using a filter-membrane-separated reactor for rapid detection of the “sniping and shooting” effect. Secreted fusion proteins are diffused in the culture medium, through the filter membrane, and bind to target cellular surfaces. In this system, GM cells were named as sniper cells, and non-GM cells as target cells.

**Fig. 1 Scheme of molecular sniping and shooting method (MSSM)** A: Surface modified non-GMOs are constructed as follows: non-GMOs were cocultivated with GM yeasts, which produce recombinant proteins with the “binding domain” and “functional domain”, the “sniping and shooting” domain on the surface of non-GMOs. B: The interactions between recombinant proteins and the surface of non-GMOs are based on the molecular recognition activity of lectins. In spite of cocultivation of non-GMOs and GM yeasts, there are no contaminations, because, in the cultivation chamber (Millicell), they are separated by the special membrane filter. The pore size of the membrane is 0.4 μm and it allows recombinant proteins to pass through, but not large cells like yeasts. Sniper cell: GM sniper cells which secrete recombinant proteins. Target cell: non-GM target cells which receive recombinant proteins.
Materials and methods

Strains and media

Escherichia coli DH5α [F−, endA1, hsdR17 (rK− mK+), supE44, thi-1, λ−, recA1, gyrA96, ΔlacU169 (φ80lacZΔM15)] was used both as a host for recombinant DNA manipulation and as a target cell. Saccharomyces cerevisiae strain MT8-1 [MATa, ade, his3, leu2, trp1, ura3] (Tajima et al. 1985) was used to produce recombinant proteins.

Saccharomyces cerevisiae strain BY4741 [MATa, his3-1, leu2, met15, ura3], BY4741ΔCYC8 [MATa, his3-1, leu2, met15, ura3, ΔCYC8] (Conlan et al. 1999), and Candida albicans NBRC1594 were used as target cells for targeting recombinant proteins. S. cerevisiae BY4741 and BY4741ΔCYC8 were obtained from Euroscarf. E. coli was grown in Luria–Bertani medium (1% (w/v) tryptone, 0.5% (w/v) yeast extract, 0.5% (w/v) sodium chloride, and 0.1% (w/v) ampicillin). Yeast was grown either in yeast peptone dextrose (YPD) medium (1% (w/v) yeast extract, 2% (w/v) polypeptone, and 2% (w/v) glucose) or SD-W (synthetic dextrose–tryptophan) medium (0.67% (w/v) yeast nitrogen base without amino acids, 2% (w/v) glucose, 0.002% adenine sulfate, 0.002% L-histidine-HCl, 0.003% L-leucine, and 0.002% uracil).

Plasmid construction and yeast transformation

Two expression vectors, pSDLn4 and pSDLc4, were designed for the N-terminal-free type and C-terminal-free type of enhanced green fluorescent protein (EGFP) for display, respectively. In short, human-placenta-cDNA-derived CTLD and glucoamylase secretion signal-EGFPFLAG domains were inserted to the multicloning site of pWGP3 (Takahashi et al. 2001).

All polymerase chain reaction (PCR) amplifications were carried out using KOD-Plus-DNA polymerase (Toyobo, Osaka, Japan). Table 1 shows the used primers. EGFP sequence was amplified from pEGFP (Takara Bio, Otsu, Japan) using primers (see in Table 1) EGYL-F(Bgl II) and EGY-R(Sal I). Amplified EGFP sequence was ligated into the plasmid pMWFD (Kuroda and Ueda 2005) using the Bgl II and Sal I sites. The resulting plasmid was named pKGD1C. EGFP-FLAG-α-agglutinin sequence was amplified from pKGD1C using primers EGFP-F(Xho I) and KpnI-R(AG). Amplified EGFP-FLAG-α-agglutinin sequence was ligated into the plasmid pCAS1 (Shibasaki et al. 2001) using the Xho I and Kpn I sites. The resulting plasmid was named pKGD2. Glucoamylase secretion signal, EGFP, and FLAG sequences were amplified from pKGD2 using primers (see in Table 1) EGFPF1 and EGFPRI-1 (for pSDLn4) or EGFPF1 and EGFPRI-2 (for pSDLc4). The CTLD sequence was amplified from human placenta cDNA (BioChain Institute, CA, USA) by PCR using the primer pairs SP-DF2-1 and SP2RXKEX2Bgl20712 (for pSDLn4), and SP-Df2-2 and SP-DtaaRXKEX2 (for pSDLc4). To construct pSDLn4 and pSDLc4, amplified EGFP fragments were ligated into the multicopy expression plasmid pWGP3 using the Kpn I and BamH I sites. The resulting plasmid was cleaved with Mlu I and BamHI I (for pSDLn4) or Bgl II and Xho I (for pSDLc4) and ligated with the CTLD fragment using the restriction sites Mlu I and BamHI I,
or Bgl II and Xho I, respectively. All amplification products were purified, and their sequences were confirmed by DNA sequencing. The resulting plasmids pSDLn4, pSDLc4, and pWGP3 (control) were introduced into S. cerevisiae by the lithium acetate method (Ito et al. 1983). Transformed cells were inoculated on the SD-W plates for 2 days at 30°C.

Table 1 Primers used in Chapter III

<table>
<thead>
<tr>
<th>Plasmid</th>
<th>Name of primer</th>
<th>Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>pKGD1C</td>
<td>SP-Df2-1</td>
<td>5’-CGACGCCGCTGGGGGAGAAGATTTTCC-3’</td>
</tr>
<tr>
<td>pKGD2</td>
<td>SP-Df2-2</td>
<td>5’-CGACGCCGCTGGGGGAGAAGATTTTCC-3’</td>
</tr>
<tr>
<td>pSDLn4</td>
<td>SP-Df2-2</td>
<td>5’-CGACGCCGCTGGGGGAGAAGATTTTCC-3’</td>
</tr>
<tr>
<td>pSDLc4</td>
<td>SP-Df2-2</td>
<td>5’-CGACGCCGCTGGGGGAGAAGATTTTCC-3’</td>
</tr>
</tbody>
</table>

Fluorescence-activated cell sorting analysis

Because cocultivation was performed in small scale (using 24-well plate and cell culture insert, total volume was 1 ml), we used cell sorter to quantify EGFP transfer from GM cells to non-GM cells. The transformants were grown in 10 ml of preculture medium (SD-W containing 0.5% (w/v) casamino acids (SDC-W)) for 28 h at 30°C with shaking. Cell cultures were then inoculated into 100 ml of the main culture medium (SDC-W) at A600 of 0.01 and incubated at 30°C with shaking. After 24, 48, and 96 h, cells were collected and centrifuged in 1.5 ml tubes at 10,000×g for 1 min. Cell pellets were collected and washed with 500 μl of phosphate-buffered saline (PBS; 137 mM NaCl, 8.1 mM Na2PO4, 2.68 mM KCl, 1.47 mM KH2PO4, pH 7.4, Nippon Gene, Tokyo, Japan) and centrifuged in the same conditions. Obtained cell pellets were suspended in PBS and measured immediately with a cell sorter (JSAN, Bay Bioscience, Kobe, Japan) using the detection channel FLT1 (535DF45). In each case, the fluorescence of 40,000 cells was acquired.

For quantification of target cells prepared by MSSM, 10 μl samples of each co-cultivation medium were collected into 5 ml polystyrene tubes (Becton, Dickinson and Company, NJ, USA) and stored on ice. PBS (1 ml) was added to each sample. After 5 min of sonication using an ultrasonic washing machine (VS-25, VELVO-CLEAR, Osaka, Japan) at 40 kHz and room temperature, 10,000 cells were immediately analyzed using a cell sorter. The percentage of cells with high fluorescence intensity was calculated with respect to the total number of cells. Sonication was carried out to
separate aggregated cells (Kon et al. 2005), which facilitates cell sorting.

For re-cultivation of cells, 20 µl samples of each co-cultivation medium were collected into 5 ml polystyrene tubes, and 1 ml of PBS was added to each sample. After 5 min of sonication (40 kHz at room temperature), 10,000 cells were immediately analyzed using a cell sorter and 1,000 cells with a high fluorescence intensity were sorted and spread onto agar medium as described below. Cell viability was calculated by counting colonies formed on the plate. Colonies were also used for colony PCR as described below.

Cocultivation of GM and non-GM cells using membrane filter

To transfer fluorescence from GM cells to non-GM cells as they grow in the medium in which these cells are separated by a filter membrane, GM and non-GM cells were co-cultivated as follows. Non-GM cells (cells with the receptor as target cells) were inoculated into each well of a 24-well plate at 6.5×10^5 cells in a volume of 200 µl. A cell culture insert, Millicell (hanging type, membrane filter with a pore size of 0.4 µm; Millipore, Billerica, USA, see Fig. 1) was set into each well, then GM cells (cells with releasing function as sniper cells) were inoculated into Millicell for 1.3×10^6 cells in a volume of 600 µl. In the case of the BY4741ΔCYC8 strain, 200 µl of SDC-W was added into Millicell after 65 h of cocultivation. As a control, non-GM cells were inoculated into 24-well plates as target cells: in this case, Millicell was not inserted into the wells. After co-cultivation at 30°C with shaking at 1,200 rpm, cells were harvested, and in each sample, fluorescence intensity was measured using a cell sorter. For microscopic observation, yeast cells were washed with PBS twice and observed by fluorescence microscopy.

Sodium dodecyl sulfate polyacrylamide gel electrophoresis and Western blotting of GM cell lysates and supernatants

Yeast cells transformed with pSDLn4 and pSDLc4 were grown in 100 ml of SDC-W medium for 2 days after pre-culture. Cells were then collected by centrifugation at 20,000×g for 20 min at 4°C. Supernatants were filtrated using 0.2 µm Steradisc (Kurabo, Osaka, Japan) and concentrated by ultrafiltration using Microcon YM-30 filters (Millipore). Cell pellets were washed with 50 ml of 50 mM Tris–HCl (pH 7.8) containing 5 mM ethylenediamine tetraacetic acid and 8 M urea twice and centrifuged under the same condition. Cells were homogenized using glass beads (3,000 rpm at 4°C for 1 min, twice). Supernatants were collected by centrifugation at 20,000×g for 20 min at 4°C. After filtration using a 0.2-µm Steradisc, lysates were concentrated by ultrafiltration using Microcon YM-30 filters. Concentrated supernatants were analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) using PAGEL 5–20% gradient gel (Atto, Tokyo, Japan) and by Western blotting. For Western blotting, an anti-flag antibody conjugated with horseradish peroxidase was used at a volume of 1:1,000.
**Blue native-PAGE of GM cell lysates**

Yeast cells transformed with pSDLn4, pSDLc4, and pWGP3 were subjected to the glass bead method as described above. Using supernatants obtained, blue-native PAGE (BN-PAGE) was performed as previously reported (Wittig et al. 2006) with native PAGETM 4–16% bis–Tris gel (Invitrogen, CA, USA).

**Results**

**Production of EGFP fusion proteins by GM yeast**

The plasmids pSDLn4 and pSDLc4 for the N-terminal- and C-terminal-free display of EGFP (Fig. 2) were constructed, respectively. Growth-phase-related production of the EGFP-fusion protein was observed by fluorescence microscopy and fluorescence-activated cell sorting (FACS) analysis (Fig. 3). In the early growth phase, yeast cells transformed with pSDLn4, pSDLc4, and pWGP3 (control) did not show any fluorescence. In the stationary phase, yeast cells transformed with pSDLn4 and pSDLc4 showed green fluorescence inside and in the periphery of each cell. Observed fluorescence indicates the EGFP fusion proteins on the way of secretion from GM sniper yeasts. FACS analysis showed a marked change in subcellular fluorescence intensity. SDS-PAGE and Western blotting also showed the production of FLAG-conjugated recombinant proteins. These results demonstrated the production of EGFP fusion proteins from GM sniper yeasts and suggested the secretion of these proteins from cells.

**Fig. 2 Plasmids constructed in this study for MSSM**

Plasmids pSDLn4 and pSDLc4 were constructed for N-terminal-free and C-terminal-free EGFP surface display of non-GMO, respectively. In accompany with the secretion signal sequence, EGFP fragment was fused to N- or C-terminal of CTLD. Between EGFP fragment and CTLD was a FLAG-tag for immunodetetion. pWGP3 as control was used as the cassette vector in which the constructs were introduced. PGAP: GAPDH promoter, TGAP: GAP terminator
Transfer of EGFP fluorescence from GM sniper yeast to non-GM target cells in co-cultivation

To investigate the targeting of recombinant EGFP proteins from GM sniper to non-GM target yeast cells, we cocultivated GM sniper and non-GM target cells using Millicell (Millipore) as shown in Fig. 1. After cocultivation using 24-well plates and the Millicell system, BY4741ΔCYC8, one of the target cells, showed a marked increase in fluorescence intensity, as determined by FACS analysis (Fig. 4). Observation under a fluorescence microscope confirmed the green fluorescence on the surface of BY4741ΔCYC8 strain cells examined, as shown in Fig. 4. There was no increase in fluorescence intensity on other examined strains. These results suggest that the specific display of recombinant EGFP on target yeast cells (in this case, BY4741ΔCYC8) succeeded. The target yeast cell represents a specific state of non-GM cells (Conlan et al. 1999). To evaluate whether the recombinant EGFP forms were trimers, BN-PAGE and Western blotting were performed (Fig. 3). BN-PAGE analysis showed that the fusion protein produced by GM sniper yeast cells was a monomer, judging from the result of SDS-PAGE.

Confirmation of survival of targeted cells after treatment with MSSM

MSSM alters properties of living cells without genetic modifications. This is the difference of MSSM from previous methods involving chemical treatments (Bosma et al. 2006). Therefore, cells used for MSSM should survive after cocultivation. We confirmed that cells were alive after treatment with MSSM by sorting and seeding 1x10³ cells onto agar medium and calculating their viability. As a result, the pSDLc4-transformant and BY4741ΔCYC8 both survived on the SDC-W agar medium. Almost all the BY4741ΔCYC8 cells formed colonies. For each colony, colony PCR was performed to confirm that there were no plasmids in non-GM target cells. It was proved that GM target cells survived and did not contain plasmids. On YPD medium, the average viability of BY4741ΔCYC8 after 4 days of co-cultivation was 51.6% (n=3) when compared to the viability of cells before co-cultivation.

Specificity of CTLD produced by GM sniper cells

We investigated whether other strains can be target cells besides the specific BY4741ΔCYC8 strain. We examined changes of fluorescence intensity in the S. cerevisiae BY4741 and MT8-1 strains and C. albicans after targeting with MSSM. After 1, 2, and 4 days of co-cultivation, all the strains showed nearly no transfer of fluorescence (Fig. 5).
Fig. 3 Recombinant fusion proteins produced and secreted from GM sniper cells Phase contrast and fluorescence observation is shown (A). In fluorescence microscopy (Right), yeast cells transformed with pSDLn4 and pSDLc4 showed green fluorescence inside and in the periphery of the cells, while yeast cells transformed with pWGP3 showed no fluorescence. In FACS analysis (B) showed that from early growth phase (white area) to stationary phase (gray area), yeast cells transformed with pSDLn4 and pSDLc4 showed marked change of fluorescence intensity and subcellular localization. At stationary phase, as the percentage of cells with high (> 28) fluorescence intensity (% Total cells) was 5.28 %, 74.2 %, 76.7 % (At early growth phase, the percentage was 1.44 %, 9.65 %, 14.2 %) for yeast cells transformed with pWGP3, pSDLn4, and pSDLc4, respectively. SDS-PAGE (C, Western blotting) and BN-PAGE (D, Western blotting): yeast cells transformed with pWGP3 (pW), pSDLn4 (n4), and pSDLc4 (c4) were homogenized, and lysates (lys) and supernatant of culture medium, in C, were analyzed by Western blotting. Samples from yeast cells transformed with pSDLn4 and pSDLc4 showed each single band. Closed circle indicates the observed band of fusion proteins. Mr standard markers (Full range rainbow marker; GE Healthcare, Stockholm, Sweden) were used. n4/ c4/ pW: supernatants, n4 lys/ c4 lys/ pW lys: lysates
Fig. 4 Demonstration of transfer of recombinant proteins to non-GM S. cerevisiae BY4741ΔCYC8 target cells from GM sniper cells
After 0, 2, and 4 days of co-cultivation with GM sniper cells, non-GM target cells (S. cerevisiae BY4741ΔCYC8) was analyzed using the cell sorter. As a control, the same strain was cultivated in 24-well plate. After 2 and 4 days, co-cultivated non-GM yeast showed marked shift of fluorescence intensity. The percent total cells defined in Fig. 3 that showed over 28 of fluorescence intensity increased from 2 to 4 days. By fluorescence microscopic observation, co-cultivated non-GM target yeast cells clearly showed green fluorescence on the surface of the cells (photos). Graph shows the presentation of percent total cells that exhibited fluorescence intensity >28 in each stage. White bars control, black bars co-cultivated BY4741ΔCYC8

Fig. 5 Specificity of non-GM target cells as receiver cells
S. cerevisiae MT8-1, BY4741, BY4741ΔCYC8 strains, and C. albicans were co-cultivated with GM sniper cells. As a control, the same strain was cultivated in 24-well plate. After 1, 2, and 4 days, co-cultivated cells and control cells were analyzed using the cell sorter. The average count of percent total cells that showed fluorescence intensity (>28) were represented. Percent total cell count of control cells was subtracted from each count. Open circle S. cerevisiae MT8-1, closed circle S. cerevisiae BY4741ΔCYC8, open square C. albicans, X S. cerevisiae BY4741
Development of a novel instrument for large-scale co-cultivation

Instruments for large-scale co-cultivation of microbes were developed with aids of Sanki-seiki and Geo support. The instrument has two compartments that are separated by filter membranes, which arrow proteins and small molecules to pass through but not cells (Fig. 6).

![Fig. 6 Development of a novel instrument for large-scale co-cultivation](image)

Discussion

The targeting of the recombinant protein from GM sniper to living non-GM target cells using a novel co-cultivation system with a membrane filter was demonstrated. The protein targeting system was designated as the molecular sniping and shooting method (MSSM). MSSM has the following features: it allows analysis of two different strains in co-cultivation state separately and simultaneously; and it allows production of non-GM target cells with the ability derived from functional recombinant proteins without self-production in a living state.

In MSSM, non-GM target strains showed a marked increase in fluorescence intensity, which indicates the recombinant fusion proteins were produced and secreted by GM sniper cells to non-GM target cells in the filter membrane-separated reactor (Fig. 4). These results indicate that fusion proteins produced by GM sniper cells were specifically targeted on the surface of non-GM target cells. The co-cultivation test showed that *S. cerevisiae* MT8-1 strain hardly binds the constructed fusion proteins on its surface. Therefore, *S. cerevisiae* MT8-1 cells were suitable as GM sniper yeast cells in the present study.

BN-PAGE analysis showed that the constructed fusion protein was a monomer. The fusion protein contains the CTLD of human SP-D, which was reported to have no binding activity in the monomer state; it is required to be a trimmer to exhibit binding ability to lipopolysaccharides and
phospholipids (Kishore et al. 1996) and bacteria (Eda et al. 1997). However, interestingly, our fusion proteins bound to its ligand in the monomer state. The observation that C. albicans (previously reported suitable strain for SP-D) showed no change in the fluorescence intensity (Fig. 5) also suggests that CTLD used in MSSM exhibited the interesting change of property of its binding target.

Summary

A novel method was developed to coat living wt cells with functional recombinant proteins. First, I prepared yeast cells to secrete constructed proteins that have two domains: a functional domain and a binding domain that recognizes other cells. Second, I co-cultivated recombinant protein-secreting cells and wt cells that share and co-utilize the medium containing recombinant using a filter-membrane-separated cultivation reactor. Engineered yeast cells secreted enhanced green fluorescent protein (EGFP) fusion proteins to culture medium. After co-cultivation, EGFP fusion proteins were targeted to \textit{Saccharomyces cerevisiae} BY4741ΔCYC8 cell surface. In addition, I participated in developing novel culture devises for large scale co-cultivation.

References


GENERAL CONCLUSION

The present study was conducted to reveal the molecular basis of the moonlighting protein enolase, particularly focusing on mechanisms regulating inter- and intracellular localization.

In chapter I, the Eno2p secretion pathway was investigated. It was revealed for the first time that Eno2p was secreted via a SNARE protein Tlg2p-driven unknown secretion pathway. In the study, the N-terminal amino acid region of Eno2p was found to be secreted while forming foci in the cell. The results suggested that the N-terminal region of Eno2p may be the region regulating Eno2p localization.

In chapter II, the first N-terminal foci-forming region was investigated in detail. It was found that the (5–25)-amino acid region was sufficient for foci formation. In addition, alanine substitution of the V22 residue was found to inhibit foci formation. Next, the correlation between the foci and localization of full-length Eno2p was investigated. Full-length Eno2p was found to form foci under hypoxia. Because V22 substitution to alanine diminished the foci-forming property of full-length Eno2p and both foci formed by the N-terminal region and full-length Eno2p colocalized, localization change in Eno2p is suggested to be regulated by the N-terminal region. Furthermore, the mechanisms and biological effects of the foci were investigated. Foci formation under hypoxia was regulated by the sensing pathway of mitochondrial ROS production. Moreover, the correlation between the changes in the metabolic pathway and foci formation in the cell suggests the role of the foci as a metabolic regulator. The universality of the sensing and glycolytic pathways suggests that foci formation is a conserved way of regulating cellular physiology.

In chapter III, novel methods and instruments for investigating extracellular roles of moonlighting proteins were prepared. Using these, the unknown functions of secreted enolase in *Saccharomyces cerevisiae* will be revealed.

In summary, the findings of present study suggest that the spatial reorganization of proteins regulates cellular physiology.
ACKNOWLEDGEMENTS

This thesis is submitted by the author to Kyoto University for the Doctor degree of Agriculture. The studies presented here have been carried out under the direction of Professor Mitsuyoshi Ueda in the Laboratory of Biomacromolecular Chemistry, Division of Applied Life Sciences, Graduate School of Agriculture, Kyoto University.

I would like to express my sincere gratitude to Professor Dr. Mitsuyoshi Ueda for his continuous guidance, patience, and encouragements. I am deeply grateful to Associate Professor Dr. Kouichi Kuroda for his support, guidance, understanding and encouragements throughout my laboratory life. I am also deeply grateful to Assistant Professor Dr. Hironobu Morisaka for his understanding, encouragements, continuous support and collaborations. I would like to express my sincere appreciation to Secretary Fukuko Suzuki to her understanding, patience and kindhearted support throughout my laboratory life. My deep appreciation goes to all the present and past members of Prof. Ueda’s laboratory for their constant encouragement and support throughout this work.

I am deeply grateful to Dr. Masahiro Takagi, Professor of Japan Advanced Institute of Science and Technology, for his guidance, helpful collaboration, and warmhearted encouragements. I also thank all the members of Prof. Takagi’s laboratory for their kindness supports.

I am also deeply grateful to Yasuhiro Sato of Carl Zeiss Microscopy Co., Ltd for his continuous and patient technical supports, helpful collaboration, and warm encouragements.

I would like to sincerely thank Dr. Hiro-o Hamaguchi, former Professor of Tokyo University and current Professor of Waseda University, for his kindness support, discussions, and encouragements on this work. I would like to thank Dr. Chikao Onogi and Taiga Wada of Prof. Hamaguchi’s laboratory, for their technical supports and thoughtful discussions related to this work.

I would like to gratefully thank Dr. Wataru Fujibuchi, Professor of Kyoto University, for his continuous warm encouragements and thoughtful discussions on this work.

I gratefully acknowledge Dr. Hiroshi Harada, Principal Investigator of Group of Radiation and Tumor Biology, Career-Path Promotion Unit for Young Life Scientists, Kyoto University, for his suggestions and productive discussions on cell physiology under hypoxia.

I would like to sincerely thank Dr. Eiichiro Fukusaki, Professor of Osaka University for his thoughtful suggestions and helpful discussions on metabolic analysis, and continuous warm encouragements.

I would like to thank Dr. Randy Schekman at University of California, Berkeley, for providing the RSY282 (sec23-1) strain.

I acknowledge The JSPS Research Fellowships for Young Scientists [09J02920] from the Japan Society for the Promotion of Sciences.

Finally, I would like to sincerely thank my parents and brothers, Jirou, Futaba, Takurou, and Akira, for their deep understanding, continuous encouragements, and supports.
CHAPTER I
Miura, N., Kirino, A., Endo, S., Morisaka, H., Kuroda, K., Takagi, M., and Ueda, M.
Tracing putative trafficking of glycolytic enzyme enolase via SNARE-driven unconventional secretion

CHAPTER II
Miura, N., Shinohara, M., Tatsukami, Y., Sato, Y., Morisaka, H., Kuroda, K., and Ueda, M.
Spatial reorganization of yeast enolase to switch carbon metabolic pathway under hypoxia
Submitted

CHAPTER III
Miura, N., Aoki, W., Tokumoto, N., Kuroda, K., and Ueda, M.
Cell surface modification for non-GMO without chemical treatment by novel GMO-coupled and -separated cocultivation method

Other publications
In English
Shinya, R., Takeuchi, Y., Miura, N., Kuroda, K., Ueda, M., and Futai, K.
Surface coat proteins of the pine wood nematode, _Bursaphelenchus xylophilus_: profiles of stage and isolate-specific characters

Aoki, W., Kitahara, N., Miura, N., Morisaka, H., Yamamoto, Y., Kuroda, K., and Ueda, M.
Comprehensive characterization of secreted aspartic proteases encoded by a virulence gene family in _Candida albicans_
_J. Biochem._, **150**, 431-438 (2011)

Aoki, W., Kitahara, N., Miura, N., Morisaka, H., Kuroda, K., and Ueda, M.
Profiling of adhesive properties of the agglutinin-like sequence (ALS) protein family, a virulent attribute of _Candida albicans_
Aoki, W., Kitahara, N., Miura, N., Morisaka, H., Yamamoto, Y., Kuroda, K., and Ueda, M. 
*Candida albicans* Possesses Sap7 as a Pepstatin A-Insensitive Secreted Aspartic Protease

Aoki, W., Kitahara, N., Miura, N., Morisaka, H., Kuroda, K., and Ueda, M. 
Design of a novel antimicrobial peptide activated by virulent proteases

Fushimi, T., Miura, N., Shintani, H., Tsunoda, H., Kuroda, K., and Ueda, M. 
Mutant firefly luciferases with improved specific activity and dATP discrimination constructed by yeast cell surface engineering

**In Japanese**
◆総説
黒田浩一、三浦夏子、植田充美，『バイオマスデザインに向けた植物育種の新発想』，

黒田浩一、三浦夏子，『金属イオン吸着・回収に向けた細胞表層デザインと吸着分子の創製』，
「日本生物工学会誌」, 86(6), 280-282 (2008)

◆書籍
三浦夏子、林絵理、植田充美，「シングルセル解析の最前線」(神原秀記・松永是・植田充美監修)，『変異タンパク質およびタンパク質ドメインを用いた short RNA の回収、分離技術 (p. 142-148)』シーエムシー出版, 2010.